COVID-19神経ハンドブック

出版社： 中外医学社
著者：
発行日： 2022-05-30
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784498328860
電子書籍版： 2022-05-30 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,280 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

COVID-19の急性期の神経筋症状，brain fog，頭痛，嗅覚・味覚障害，自律神経障害などのコロナ後遺症（long COVID），ワクチンと副反応など，予後・QOLに大きく関わる神経筋症状について，臨床の疑問に答え診療に役立つ解説を1冊に！　疑問の多い新型コロナウイルス感染症の神経症状を解き明かす，未曽有の危機に全力で立ち向かう医師のための必読書．

目次

  • I 総論
    　1．Neuro-COVID-19　―全経過でみられる臨床症候―
    　2．疫学データから考える今後の展望と指針

    II 神経障害の機序
    　1．新型コロナウイルス（SARS-CoV-2）とCOVID-19
    　2．血管への感染と血液脳関門の破綻
    　3．血栓形成と凝固異常
    　4．COVID-19 における免疫応答─ Neuro-COVID-19 を理解するために─
    　5．サイトカインストームと脳への影響
    　6．COVID-19 の神経系画像所見
    　7．COVID-19 の神経病理所見

    III Neuro-COVID（COVID-19 に伴う神経合併症）
    　1．新型コロナウイルス感染症（COVID-19）の全身症状
    　2．世界のレジストリ研究
    　3．COVID-19 重症例の神経学的特徴
    　4-1）嗅覚・味覚障害（急性期）─臨床
    　4-2）嗅覚障害（急性期）─基礎研究
    　5．COVID-19 関連頭痛（急性期）
    　6．脳血管障害（医原性を除く）
    　7．脳炎・脳症
    　8．MS，NMOSD，抗MOG 抗体関連疾患
    　9．神経筋接合部疾患
    　10．運動異常症
    　11．運動失調症
    　12．COVID-19 に伴う急性脊髄炎
    　13．COVID-19 に関連した末梢神経障害
    　14．COVID-19 と筋障害
    　15．医原性神経障害

    IV パンデミック禍の神経診療の注意点と課題
    　1．神経救急と神経集中治療
    　2．脳卒中診療
    　3．COVID-19 の認知症者への影響
    　4．神経難病診療
    　5．神経免疫疾患診療
    　6．睡眠呼吸障害診療
    　7．リハビリテーション診療
    　8．神経病理への影響と課題
    　9．ポストコロナで求められる同期/ 非同期型臨床教育
    　10．医療者のバーンアウトへの影響と課題

    V Long COVID と神経・精神症状
    　1．後遺症概論（用語の整理，WHO の定義を含む）
    　2．認知機能障害，Brain fog（ブレインフォグ），睡眠障害
    　3．運動不耐
    　4．自律神経異常症
    　5．頭痛（後遺症・ワクチン後）・疼痛症候群
    　6．精神症状（不安・うつ・自殺）
    　7．嗅覚障害，味覚障害（後遺症）
    　8．Long COVID に対する脳神経内科的アプローチと課題

    VI ワクチンと副反応
    　1．ワクチンの有効性と副反応
    　2．VITT とpre-VITT 症候群
    　3．Guillain-Barré 症候群，顔面神経麻痺
    　4．COVID-19 感染後・同ワクチン接種後の機能性運動異常症
    　5．神経免疫疾患におけるCOVID-19 ワクチン接種

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.7 掲載の参考文献
1) Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 ; 77 : 683-90.
 
2) Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19 : The ALBACOVID registry. Neurology. 2020 ; 95 : e1060-70.
PubMed
3) Moro E, Priori A, Beghi E, et al. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur J Neurol. 2020 ; 27 : 1727-37.
PubMed
4) Garcia-Monco JC, Muras AC, Iriarte ME, et al. Neurological manifestations in a prospective unselected series of hospitalized patients with COVID-19. Neurol Clin Pract. 2021 ; 11 : e64-e72.
 
5) Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020 ; 7 : 2221-30.
PubMed
6) Toptan T, Aktan C, Basari A, et al. Case series of headache characteristics in COVID-19 : Headache can be an isolated symptom. Headache. 2020 ; 60 : 1788-92.
PubMed
7) Membrilla JA, de Lorenzo I, Sastre M, et al. Headache as a cardinal symptom of coronavirus disease 2019 : A cross-sectional study. Headache. 2020 ; 60 : 2176-91.
PubMed
8) Caronna E, Ballve A, Llaurado A, et al. Headache : A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020 ; 40 : 1410-21.
PubMed
9) Chiesa-Estomba CM, Lechien JR, Radulesco T, et al. Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. Eur J Neurol. 2020 ; 27 : 2318-21.
PubMed
10) Chou SH, Beghi E, Helbok R, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19-A report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. 2021 ; 4 : e2112131.
PubMed
11) Kleineberg NN, Knauss S, Gulke E, et al. Neurological symptoms and complications in predominantly hospitalized COVID-19 patients : Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS). Eur J Neurol. 2021 ; 28 : 3925-37.
PubMed
12) Nath A. Long-haul COVID. Neurology. 2020 ; 95 : 559-60.
PubMed
13) Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 ; 27 : 601-15.
PubMed
14) World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1
 
15) Couzin-Frankel J. The long haul. Science. 2020 ; 369 : 614-7.
 
16) Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol. 2021 ; 8 : 1073-85.
PubMed
17) Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pham T, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021 ; 325 : 1525-34.
 
18) Blomberg B, Mohn KG, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021 ; 27 : 1607-13.
 
19) Hosp JA, Dressing A, Blazhenets G, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021 ; 144 : 1263-76.
PubMed
20) Hugon J, Msika EF, Queneau M, et al. Long COVID : Cognitive complaints (brain fog) and dysfunction of the cingulate cortex. J Neurol. 2022 ; 269 : 44-6.
PubMed
21) Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19 : Potential mechanisms of disease. Brain. 2021 ; 144 : 3576-88.
PubMed
22) Soares FHC, Kubota GT, Fernandes AM, et al. Prevalence and characteristics of new-onset pain in COVID-19 survivours, a controlled study. Eur J Pain. 2021 ; 25 : 1342-54.
PubMed
23) Sandler CX, Wyller VBB, Moss-Morris R, et al. Long COVID and post-infective fatigue syndrome : A review. Open Forum Infect Dis. 2021 ; 8 : ofab440.
PubMed
24) Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 ; 383 : 2603-15.
PubMed
25) Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021 ; 27 : 2144-53.
PubMed
26) Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 ; 384 : 2124-30.
PubMed
27) Kim DD, Kung CS, Perez DL. Helping the public understand adverse events associated with COVID-19 vaccinations : Lessons learned from functional neurological disorder. JAMA Neurol. 2021 ; 78 : 789-90.
PubMed
P.19 掲載の参考文献
1) Worldometers.info. Reported Cases and Deaths by Country, Territory, or Conveyance. Dover, Delaware, U.S.A 2021. https://www.worldometers.info/coronavirus/
 
2) Sonoo M, Idogawa M, Kanbayashi T, et al. Correlation between PCR examination rate among the population and the containment of pandemic of COVID-19. Public Health. 2021 ; 191 : 31-2.
PubMed
3) Sonoo M, Kanbayashi T, Shimohata T, et al. Estimation of the true infection rate and infection fatality rate of coronavirus disease 2019 in each country. J Infect Public Health. 2022 ; 15 : 210-3.
 
4) 園生雅弘, 井戸川雅史, 神林隆道, 他. 疫学データから考えるCOVID-19対策の指針. Brain and Nerve 神経研究の進歩. 2020 ; 72 : 1023-30.
 
5) 園生雅弘, 林秀行. 今後の展望. Clin Neurosci. 2021 ; 39 : 360-4.
 
6) 園生雅弘, 林秀行. 日本と世界におけるCOVID-19の疫学. 脳神経内科. 2021 ; 95 : 284-94.
 
7) Armengaud J, Delaunay-Moisan A, Thuret JY, et al. The Importance of naturally attenuated Sars-Cov-2 in the fight against Covid-19. Environ Microbiol. 2020 ; 22 : 1997-2000.
PubMed
8) Tapper J, Savage M, McKie R. End mass jabs and live with Covid, says ex-head of vaccine taskforce : Dr Clive Dix says we should treat the virus like flu. The Guardian 2022. https://www.theguardian.com/world/2022/jan/08/end-mass-jabs-and-live-with-covid-says-ex-head-of-vaccine-taskforce
 
9) 森田公一. 新型コロナウイルスの特徴. 医学のあゆみ. 2021 ; 276 : 4-8.
Medical*Online
10) Vijgen L, Keyaerts E, Moes E, et al. Complete genomic sequence of human coronavirus OC43 : molecular clock analysis suggests a relatively recent zoo-notic coronavirus transmission event. J Virol. 2005 ; 79 : 1595-604.
 
11) 東京都総務局総合防災部防災管理課. 【令和3年度】東京都新型コロナウイルス感染症モニタリング会議・分析資料. 東京都防災ホームページ 2022. https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html
 
12) Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022 ; 327 : 583-4.
PubMed
13) Statens Serum Institute. Status for SARS-CoV-2 varianten omikron i Danmark, 3rd January 2022. Covid-19 Rapport om omikronvarianten 2022 ; https://files.ssi.dk/covid19/omikron/statusrapport/rapport-omikronvarianten-03012022-9gj3
 
14) Idogawa M, Tange S, Nakase H, et al. Interactive web-based graphs of novel coronavirus COVID-19 cases and deaths per population by country. Clin Infect Dis. 2020 ; 71 : 902-3.
PubMed
15) 札幌医大フロンティア研ゲノム医科学. 新型コロナウイルス死者数と高齢化率【世界・国別】. 2022. https://web.sapmed.ac.jp/canmol/coronavirus/bubble.html?rg=all
 
16) 東洋経済オンライン編集部. 新型コロナウイルス国内感染の状況. 2021. https://toyokeizai.net/sp/visual/tko/covid19/
 
17) 金秀蓮. 5～11歳のワクチン接種, 「努力義務の対象外」提案へ 厚労省. 毎日新聞 2022. https://news.yahoo.co.jp/articles/912c525af451654f8718db975196a60e998f8c7a
 

II 神経障害の機序

P.27 掲載の参考文献
1) Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005 ; 310 : 676-9.
PubMed
2) Li LL, Wang JL, Ma XH, et al. A novel SARS-CoV-2 related coronavirus with complex recombination isolated from bats in Yunnan province, China. Emerg Microbes Infect. 2021 ; 10 : 1683-90.
PubMed
3) Adachi T, Chong JM, Nakajima N, et al. Clinicopathologic and immunohistochemical findings from autopsy of patient with COVID-19, Japan. Emerg Infect Dis. 2020 ; 26 ; 2157-61.
 
4) Duarte-Neto AN, Teixeira TA, Caldini EG, et al. Testicular pathology in fatal COVID-19 : A descriptive autopsy study. Andrology. 2022 ; 10 : 13-23.
PubMed
5) Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021 ; 12 : 2506.
PubMed
6) Steenblock C, Richter S, Berger I, et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun. 2021 ; 12 : 3534.
PubMed
7) Matuck BF, Dolhnikoff M, Duarte-Neto AN, et al. Salivary glands are a target for SARS-CoV-2 : a source for saliva contamination. J Pathol. 2021 ; 254 : 239-43.
PubMed
8) Nunez-Torron C, Ferrer-Gomez A, Moreno Moreno E, et al. Secondary haemophagocytic lymphohistiocytosis in COVID-19 : correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. J Clin Pathol. 2021 : jclinpath-2020-207337.
 
9) Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19-final report. N Engl J Med. 2020 ; 383 : 1813-26.
PubMed
P.35 掲載の参考文献
1) Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019 : A Review. JAMA Neurol. 2020 ; 77 : 1018-27.
PubMed
2) Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiatry. 2021 ; 78 : 682-3.
PubMed
3) Jarhult JD, Hultstrom M, Bergqvist A, et al. The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. Sci Rep. 2021 ; 11 : 7163.
 
4) Zhang BZ, Chu H, Han S, et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020 ; 30 : 928-31.
PubMed
5) Wang K, Chen W, Zhang Z, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020 ; 5 : 283.
PubMed
6) He L, Mae MA, Muhl L, et al. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2-implications for microvascular inflammation and hypercoagulopathy in COVID-19 patients. bioRxiv. 2020.
 
7) Hirunpattarasilp C, James G, Freitas F, et al. SARS-CoV-2 binding to ACE2 triggers pericyte-mediated angiotensin-evoked cerebral capillary constriction. bioRxiv. 2020.
 
8) Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 ; 203 : 631-7.
PubMed
9) Radmanesh A, Derman A, Lui YW, et al. COVID-19-associated diffuse leukoencephalopathy and microhemorrhages. Radiology. 2020 ; 297 : E223-7.
PubMed
10) Wimmer RA, Leopoldi A, Aichinger M, et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature. 2019 ; 565 : 505-10.
PubMed
11) Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020 ; 181 : 905-13 e7.
 
12) Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 ; 395 : 1417-8.
PubMed
13) Wenzel J, Lampe J, Muller-Fielitz H, et al. The SARS-CoV-2 main protease M (pro) causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci. 2021 ; 24 : 1522-33.
PubMed
14) Bocci M, Oudenaarden C, Saenz-Sarda X, et al. Infection of brain pericytes underlying neuropathology of COVID-19 patients. Int J Mol Sci. 2021 ; 22 : 11622.
PubMed
15) Wang L, Sievert D, Clark AE, et al. A human three-dimensional neural-perivascular ‘assembloid' promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology. Nat Med. 2021 ; 27 : 1600-6.
 
16) Marshall M. COVID and the brain : Researchers zero in on how damage occurs. Nature. 2021 ; 595 : 484-5.
 
17) Cardot-Leccia N, Hubiche T, Dellamonica J, et al. Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection. Intensive Care Med. 2020 ; 46 : 1777-8.
PubMed
18) Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020 ; 116 : 1097-100.
PubMed
19) Robinson FA, Mihealsick RP, Wagener BM, et al. Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. Am J Physiol Heart Circ Physiol. 2020 ; 319 : H1059-68.
PubMed
20) Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE2. Circulation research. 2021 ; 128 : 1323-6.
 
21) Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2021 ; 24 : 368-78.
PubMed
22) Khaddaj-Mallat R, Aldib N, Bernard M, et al. SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein. Neurobiol Dis. 2021 ; 161 : 105561.
PubMed
23) Avolio E, Carrabba M, Milligan R, et al. The SARS-CoV-2 spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling : a potential non-infective mechanism of COVID-19 microvascular disease. Clin Sci (Lond). 2021 ; 135 : 2667-89.
PubMed
24) 吾郷哲朗. ペリサイトは脳機能にとってなぜ重要なのか?. 臨床神経. 2019 ; 59 : 707-15.
 
25) Daneman R, Zhou L, Kebede AA, et al. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010 ; 468 : 562-6.
PubMed
26) Shibahara T, Ago T, Nakamura K, et al. Pericyte-mediated tissue repair through PDGFRβ promotes peri-infarct astrogliosis, oligodendrogenesis, and functional recovery after acute ischemic stroke. eNeuro. 2020 ; 7 : ENEURO. 0474-19.2020.
 
27) Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011 ; 12 : 723-38.
PubMed
28) Crook H, Raza S, Nowell J, et al. Long covid-mechanisms, risk factors, and management. BMJ. 2021 ; 374 : n1648.
PubMed
P.42 掲載の参考文献
1) Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 ; 382 : 1708-20.
 
2) Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 ; 18 : 844-7.
 
3) Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19 : an autopsy series from New Orleans. Lancet Respir Med. 2020 ; 8 : 681-6.
PubMed
4) Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19 : An updated analysis. Thromb Res. 2020 ; 191 : 148-50.
PubMed
5) Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy : a two-centre descriptive study. Lancet Infect Dis. 2020 ; 20 : 1135-40.
 
6) Magro CM, Mulvey J, Kubiak J, et al. Severe COVID-19 : A multifaceted viral vasculopathy syndrome. Ann Diagn Pathol. 2021 ; 50 : 151645.
 
7) Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 ; 77 : 683-90.
 
8) 日本脳卒中学会. COVID-19 対応 脳卒中プロトコル. https://www.jsts.gr.jp/news/pdf/jss_pcs_ver1_2.pdf (accessed May 11, 2020).
 
9) Avula A, Nalleballe K, Narula N, et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020 ; 87 : 115-9.
PubMed
10) Jin H, Hong C, Chen S, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol. 2020 ; 5 : 146-51.
 
11) Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet. 2020 ; 395 : 1054-62.
 
12) Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020 ; 382 : e60.
 
13) Umapathi T, Kor AC, Venketasubramanian N, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004 ; 251 : 1227-31.
PubMed
14) Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System. JAMA. 2020 ; 324 : 799-801.
 
15) Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020 ; 76 : 122-4.
PubMed
16) 日本静脈学会, 肺塞栓症研究会, 日本血管外科学会, 他. 新型コロナウイルス感染症 (COVID-19) における 静脈血栓塞栓症予防および抗凝固療法の診療指針. https://jsphlebology.jp/wp/wp-content/uploads/2021/10/20211005新型コロナウイルス感染症(COVID-19)における静脈血栓塞栓症予防の診療指針.pdf.
 
17) World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). https://apps.who.int/iris/rest/bitstreams/1357562/retrieve
 
P.50 掲載の参考文献
1) van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nature Medicine. 2022 ; 28 : 39-50.
PubMed
2) Shimohata T. Neuro-COVID-19. Clin Exp Neuroimmunol. 2021 ; 10.1111/cen3.12676.
 
3) Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 ; 181 : 271-80. e8.
 
4) Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 ; 370 : eabd4570.
PubMed
5) Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 ; 370 : eabd4585.
PubMed
6) Bastard P, Orlova E, Sozaeva L, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021 ; 218 : e20210554.
 
7) Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 ; 324 : 1279-81.
PubMed
8) Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020 ; 181 : 1489-501. e15.
 
9) Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020 ; 323 : 2249-51.
PubMed
10) Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020 ; 9 : 940-8.
PubMed
11) Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020 ; 17 : 773-5.
PubMed
12) Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020 ; 584 : 437-42.
PubMed
13) Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 ; 369 : 812-7.
PubMed
14) Kreer C, Zehner M, Weber T, et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell. 2020 ; 182 : 843-54. e12.
 
15) Kaneko N, Kuo HH, Boucau J, et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. 2020 ; 183 : 143-57. e13.
 
16) Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021 ; 595 : 283-8.
PubMed
17) Damoiseaux J, Dotan A, Fritzler MJ, et al. Autoantibodies and SARS-CoV2 infection : The spectrum from association to clinical implication : Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2021 ; 21 : 103012.
PubMed
18) Dotan A, Muller S, Kanduc D, et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021 ; 20 : 102792.
PubMed
19) Blomberg B, Mohn KG, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021 ; 27 : 1607-13.
 
20) Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022 ; 22 : e102-e107.
PubMed
21) Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021 ; 595 : 565-71.
PubMed
22) Schweitzer F, Goereci Y, Franke C, et al. Cerebrospinal fluid analysis post-COVID-19 is not suggestive of persistent central nervous system infection. Ann Neurol. 2022 ; 91 : 150-7.
 
P.57 掲載の参考文献
1) Hirano T, Murakami M. COVID-19 : A new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020 ; 52 : 731-3.
PubMed
2) Sinha P, Matthay MA, Calfee CS. Is a "Cytokine Storm" relevant to COVID-19?. JAMA Intern Med. 2020 1 ; 180 : 1152-4.
 
3) Thepmankorn P, Bach J, Lasfar A, et al. Cytokine storm induced by SARS-CoV-2 infection : The spectrum of its neurological manifestations. Cytokine. 2021 ; 138 : 155404.
PubMed
4) Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany : A post-mortem case series. Lancet Neurol. 2020 ; 19 : 919-29.
 
5) Koralnik IJ, Tyler KL. COVID-19 : A global threat to the nervous system. Ann Neurol. 2020 ; 88 : 1-11.
 
6) Vargas G, Medeiros Geraldo LH, Gedeao Salomao N, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells : Insights and perspectives. Brain Behav Immun Health. 2020 ; 7 : 100127.
PubMed
7) Garvin MR, Alvarez C, Miller JI, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020 ; 9 : e59177.
PubMed
8) Almutairi MM, Sivandzade F, Albekairi TH, et al. Neuroinflammation and its impact on the pathogenesis of COVID-19. Front Med (Lausanne). 2021 ; 8 : 745789.
PubMed
9) Perrin P, Collongues N, Baloglu S, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021 ; 28 : 248-58.
PubMed
10) Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020 ; 94 : 55-8.
PubMed
11) Dixon L, Varley J, Gontsarova A, et al. COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e789.
 
12) Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy : imaging features. Radiology. 2020 ; 296 : E119-E120.
PubMed
13) Pilotto A, Odolini S, Masciocchi S, et al. Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol. 2020 ; 88 : 423-7.
PubMed
14) Bodro M, Compta Y, Llanso L, et al. Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e821.
 
15) Benameur K, Agarwal A, Auld SC, et al. Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. 2020 ; 26 : 2016-21.
PubMed
16) Kudo T, Hayashi Y, Kunieda K, et al. Persistent intrathecal interleukin-8 production in a patient with SARS-CoV-2-related encephalopathy presenting aphasia : a case report. BMC Neurol. 2021 ; 21 : 426.
 
17) Bartley CM, Johns C, Ngo TT, et al. Anti-SARS-CoV-2 and autoantibody profiles in the cerebrospinal fluid of 3 teenaged patients with COVID-19 and subacute neuropsychiatric symptoms. JAMA Neurol. 2021 ; 78 : 1503-9.
PubMed
P.66 掲載の参考文献
1) Ellul MA, Benjamin L, Singh B, et al. Neurological association of COVID-19. Lancet Neurol. 2020 ; 19 : 767-83.
 
2) Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology : Clinical, radiological and laboratory findings. Brain. 2020 ; 143 : 3104-20.
PubMed
3) Hayashi M, Sahashi Y, Baba Y, et al. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci. 2020 ; 415 : 116941.
PubMed
4) Hernandez-Fernandez F, Valencia HS, Barbella-Aponte RA, et al. Cerebrovascular disease in patients with COVID-19 : Neuroimaging, histological and clinical description. Brain. 2020 ; 143 : 3089-103.
 
5) Ladopoulos T, Zand R, Shahjouei S, et al. COVID-19 : Neuroimaging features of a pandemic. J Neuroimaging. 2021 ; 31 : 228-43.
PubMed
6) Virhammar J, Kumlien E, Fallmar D, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020 ; 95 : 445-9.
PubMed
7) Kim CH, Je HG, Ju MH, et al. Cardiac myxoma misdiagnosed as infective endocarditis : A case of Carney complex. J Cardiothrac Surg. 2020 ; 15 : 188.
PubMed
8) Lin JE, Asfour A, Sewell TB, et al. Neurological issues in children with COVID-19. Neurosci Letter. 2021 ; 743 : 135567.
 
9) Sparr SA, Bieri PL. Infarction of the splenium of the corpus callosum in the age of COVID-19. Stroke. 2020 ; 51 : e223-6.
PubMed
10) Lin E, Lantos JE, Strauss SB, et al. Brain imaging of patients with COVID-19 : Findings at an academic institution during the hight of the outbreak in New York City. AJNR Am J Neuroradiol. 2020 ; 41 : 2001-8.
 
11) Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19. In the young. N Engl J Med. 2020 ; 382 : e60.
 
12) Tan Y-K, Goh C, Leow AST, et al. COVID-19 and ischemic stroke : A systematic review and meta-summary of the literature. J Thromb Thrombolys. 2020 ; 50 : 587-95.
 
13) Nawabi J, Morotti A, Wildgruber M, et al. Clinical and imaging characteristics in patients with SARS-CoV-2 infection and acute intracranial hemorrhage. J Clin Med. 2020 ; 9 : 2543.
 
14) Cezar-Junior AB, Faquini IV, Silva JLJ, et al. Subarachnoid hemorrhage and COVID-19 : Association or coincidence? Medicine (Baltimore). 2020 : 99 : e23862.
PubMed
15) Basirjafari S, Rafiee M, Shahhosseini B, et al. Association of pediatric COVID-19 and subarachnoid hemorrhage. J Med Viol. 2021 ; 93 : 658-60.
 
16) Given CA 2nd, Burdette JH, Elster AD, et al. Pseudo-subarachnoid hemorrhage : A potential imaging pitfall associated with diffuse cerebral edema. AJNR Am J Neuroradiol. 2003 ; 24 : 254-6.
PubMed
17) Radmanesh A, Derman A, Lui YW, et al. COVID-19-associated diffuse leukoencephalopathy and microhemorrhages. Radiology. 2020 ; 297 : E223-7.
PubMed
18) Klironomos S, Tzortzakakis A, Kits A, et al. Nervous system involvement in coronavirus disease 2019 ; Results from a retrospective consecutive neuroimaging cohort. Radiology. 2020 ; 297 : E324-34.
PubMed
19) Lewis A, Jain R, Frontera J, et al. COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement : A meta-analysis of the relationship to CSF SARS-CoV-2. J Neuroimaging. 2021 ; 31 : 826-48.
PubMed
20) Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020 ; 382 : 2268-70.
PubMed
21) Kandemirli S, Dogan L, Sarikaya ZT, et al. Brain MRI findings in patients in the intensive care unit with COVID-19 infection. Radiology. 2021 ; 297 : E232-5.
 
22) Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Intern J Infect Dis. 2020 ; 94 : 55-8.
 
23) Oka Y, Ueda A, Nakagawa T, et al. SARS-CoV-2-related progressive brain white matter lesion associated with an increased cerebrospinal fluid level of IL-6. Intern Med. 2021 ; 60 : 3167-70.
PubMed
24) Fadakar N, Ghaemmaghami S, Masoompour SM, et al. A first case of acute cerebellitis associated with coronavirus disease (COVID-19) : A case report and literature review. Cerebellum. 2020 ; 19 : 911-4.
 
25) Mereno-Escobar MC, Feizi P, Podury S, et al. Acute cerebellitis following SARS-CoV-2-infection : A case report and review of the literature. J Med Viol. 2021 ; 93 : 6818-21.
 
26) Sharma S, Ruparelia J, Bhaskar S, et al. Acute fulminant cerebellitis in children with COVID-19 infection : A rare but treatable complication. Pediatr Neurol. 2021 ; 119 : 45-7.
PubMed
27) Akcay A, Ogur M, Menentoglu ME, et al. Acute cerebellitis in MIC-C. Pediatr Infect Dis J. 2022 ; 41 : e16-8.
 
28) Povlow A, Auerbach AJ. Acute cerebellar ataxia in COVID-19 infection : A case report. J Emerg Med. 2021 ; 60 : 73-6.
PubMed
29) Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy : Imaging features. Radiology. 2020 ; 296 : E119-20.
PubMed
30) Dalamarre L, Gollion C, Grouteau G, et al. COVID-19-associated acute necrotizing encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fiber network. J Neurol Neurosug Psychiatr. 2020 ; 91 : 1004-6.
 
31) Elkady A, Rabinstein AA. Acute necrotizing encephalopathy and myocarditis in a young patient with COVID-19. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e801.
 
32) Shahab A, Arora A, Chhina SS, et al. A unique triad of invasive sinusitis, brain abscess with focal cerebritis, and COVID-19. Am J Case Reports. 2021 ; 22 : e933177.
 
33) Gupta V, Singh P, Sukriti K. Fungal brain abscess in a post COVID-19 patient. BMJ Case Reports. 2021 ; 14 : e246319.
 
34) Diwakar J, Samaddar A, Konar SK, et al. First report of COVID-19-associated rhino-orbito-cerebral mucormycosis in pediatric patients with type 1 diabetes mellitus. J Med Mycol. 2021 ; 31 : 101203.
 
35) Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2016 (COVID-19) and anosmia. JAMA Neurol. 2020 ; 77 : 1028-9.
 
36) Chiu A, Fischbein N, Wintermark M, et al. COVID-19-induced anosmia associated with olfactory bulb atrophy. Neuroradiology. 2021 ; 63 : 147-8.
PubMed
37) Khedr EM, Karim AA, Soliman RK. Case report : Acute spinal cord myelopathy in patients with COVID-19. Front Neurol. 2020 ; 11 : 610648.
PubMed
38) Eissa M, Abdelhady M, Algatami H, et al. Spinal cord infarction in a 41-year-old male patient with COVID-19. Neuroradiol J. 2021 ; 34 : 245-8.
 
39) Bax F, Gigli GL, Iaiza F, et al. Spontaneous spinal cord ischemia during COVID-19 infection. J Neurol. 2021 ; 268 : 4000-1.
PubMed
40) Schulte EC, Hauer L, Kunz AB, et al. Systematic review of cases of acute myelitis in individuals with COVID-19. Eur J Neurol. 2021 ; 28 : 3230-44.
PubMed
41) Huang HY, Shah LM, McNally JS, et al. COVID-19-associated myelitis involving the dorsal and lateral white matter tracts : A case series and review of the literature. AJNR Am J Neuroradiol. 2021 ; 42 : 1912-7.
PubMed
42) Roman GC, Gracia F, Torres A, et al. Acute transverse myelitis (ATM) : Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse effects with the ChAdOx1nCov-19 vaccine (AZD1222). Front Immunol. 2021 ; 12 : 653786.
 
43) Batum M, Ak AK, Mavioglu H. Covid-19 infection-induced neuromyelitis optica : a case report. Int J Neurosci. 2020 ; Dec 30 : 1-7.
 
44) Zhou S, Jones-Lopez EC, Soneji DJ, et al. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19. J Neuroophthal. 2020 ; 40 : 398-402.
PubMed
45) Mitry MA, Collins LK, Kazam JJ, et al. Parsonage-turner syndrome associated with SARS-CoV2 (COVID-19) infection. Clin Imaging. 2021 ; 72 : 8-10.
PubMed
46) Talamonti G, Colistra D, Crisa F, et al. Spinal epidural abscess in COVID-19 patients. J Neurology. 2021 ; 268 : 2320-66.
 
47) Sriwastava S, Shrestha AK, Khalid SH, et al. Spectrum of neuroimaging findings in post-COVID-19 vaccination : a case series and review of literature. Neurol Intern. 2021 ; 13 : 622-39.
 
48) Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022 : 43 : 3-40.
PubMed
49) Khayat-Khoei M, Bhattacharyya S, Katz J, et al. COVID-19 mRNA vaccination leading to CNS inflammation : A case series. J Neurol. 2122 ; 269 : 1093-106.
 
50) Queler SC, Towbin AJ, Milani C, et al. Parsonage-Turner syndrome following COVID-19 vaccination : MR neurography. Radiology. 2021 ; 302 : 84-7.
PubMed
P.76 掲載の参考文献
1) 亀井聡. 単純ヘルペス脳炎. 臨床とウイルス. 2017 ; 45 : 264-70.
Medical*Online
2) 亜急性硬化性全脳炎 (SSPE) 診療ガイドライン 2020. 厚生労働省科学研究 プリオン病及び遅発性ウイルス感染症に関する調査研究班.
 
3) 日本小児神経学会, 監修, 小児急性脳症診療ガイドライン策定委員会, 編. 小児急性脳症診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
4) 山田晋一郎, 安井敬三, 長谷川康博, 他. パンデミック (H1N1) 2009 インフルエンザ脳症の1剖検例. 臨床神経. 2012 ; 52 : 480-5.
 
5) Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005 ; 202 : 415-24.
PubMed
6) Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS) : a report from China. J Pathol. 2003 ; 200 : 282-9.
 
7) van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol. 2015 ; 235 : 175-84.
PubMed
8) Copin MC, Parmentier E, Duburcq T, et al. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020 ; 46 : 1124-6.
PubMed
9) Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany : A post-mortem case series. Lancet Neurol. 2020 ; 19 : 919-29.
 
10) Al-Sarraj S, Troakes C, Hanley B, et al. Invited review : The spectrum of neuropathology in COVID-19 (2021). Neuropathol Appl Neurobiol. 2021 ; 47 : 3-16.
PubMed
11) Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020 ; 92 : 699-702.
PubMed
12) Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003 ; 426 : 450-4.
PubMed
13) Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 ; 181 : 271-80.
PubMed
14) Chen R, Wang K, Yu J, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021 ; 11 : 573095.
PubMed
15) Kirschenbaum D, Imbach LL, Rushing EJ, et al. Intracerebral endotheliitis and microbleeds are neuropathological features of COVID-19. Neuropathol Appl Neurobiol. 2020 ; 00 : 1-6. https://doi.org/10.1111/nan.12677
 
16) Lee M-H, Perl DP, Nair G, et al. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2021 ; 384 : 481-3.
PubMed
17) von Weyhern CH, Kaufmann I, Neff F, et al. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020 ; 395 : e109.
PubMed
18) Nasrallah MP, Mourelatos Z, Lee EB. Neuropathology associated with SARS-CoV-2 infection. Lancet. 2021 ; 397 : 277.
PubMed
19) Glatzel M, Hagel C, Matschke J, et al. Neuropathology associated with SARS-CoV-2 infection. Lancet. 2021 ; 397 : 276.
PubMed
20) Egervari K, Thomas C, Lobrinus JA, et al. Neuropathology associated with SARS-CoV-2 infection. Lancet. 2021 ; 397 : 276-7.
PubMed
21) Lee JC, Nallani R, Cass L, et al. A systematic review of the neuropathologic findings of post-viral olfactory dysfunction : Implications and novel insight for the COVID-19 pandemic. Am J Rhinol Allergy. 2021 ; 35 : 323-33.
 
22) Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021 ; 24 : 168-75.
PubMed
23) Vaira LA, Hopkins C, Sandison A, et al. Olfactory epithelium histopathological findings in long- term coronavirus disease 2019 related anosmia. J Laryngol Otol. 2020 ; 1-5.
 
24) Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021 ; 184 : 5932-49.e15.
 
25) Ho C, Salimian M, Hegert J, et al. Postmortem assessment of olfactory tissue degeneration and microvasculopathy in patients with COVID-19. JAMA Neurol. 2022 Apr 11. doi : 10.1001/jamaneurol.2022.0154.
 
26) 日本病理学会のホームページ. https://pathology.or.jp/news/iryougyoumu/20200527info-2.html (2020年5月27日)
 
27) the International Society of Neuropathology (ISN) Collaborative Efforts. https://www.intsocneuropathol.com/2020/04/accessing-covid-19-braintissue/
 
28) the COVID-19 Virtual Biobank at the University of Nebraska Medical Center. https://covidbank.unmc.edu/
 
29) Hoffman LA, Vilensky JA. Encephalitis lethargica : 100 years after the epidemic. Brain. 2017 ; 140 : 2246-51.
PubMed

III Neuro - COVID ( COVID - 19 に伴う神経合併症 )

P.82 掲載の参考文献
1) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ; 395 : 497-506.
 
2) Yan CH, Faraji F, Prajapati DP, et al. Self-reported olfactory loss associates with outpatient clinical course in COVID-19. Int Forum Allergy Rhinol. 2020 ; 10 : 821-31.
PubMed
3) Tabata S, Imai K, Kawano S, et al. Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship : a retrospective analysis. Lancet Infect Dis. 2020 ; 20 : 1043-50.
 
4) 国立国際医療研究センター. COVID-19 レジストリ研究 "ダッシュボード". [Available from : https://covid-registry.ncgm.go.jp/dashboard/]
 
5) 日本耳鼻咽喉科頭頸部外科学会. 新型コロナウイルス感染症 (オミクロン株) による上気道狭窄への注意喚起 2022. [Available from : http://www.jibika.or.jp/members/covid19/covid19_220304.pdf]
 
6) Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments : A Retrospective Cohort Study. Ann intern Med. 2022 Mar 15 ; M22-0308.
 
P.90 掲載の参考文献
1) https://ourworldindata.org/coronavirus
 
2) Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 ; 382 : 1708-20.
 
3) Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020 ; 94 : 55-8.
PubMed
4) Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy : imaging features. Radiology. 2020 ; 296 : e119-20.
PubMed
5) Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19 : A single center, retrospective, observational study. Stroke Vasc Neurol. 2020 ; 5 : 279-84.
 
6) Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020 ; 382 : 2574-6.
PubMed
7) Mao L, Jin H, Wang M, et al. Neurological manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, china. JAMA Neurol. 2020 ; 77 : 683-90.
 
8) Meppiel E, Peiffer-Smadja N, Maury A, et al. Neurologic manifestations associated with COVID-19 : a multicenter registry. Clin Microbiol Infect. 2021 ; 27 : 458-66.
PubMed
9) Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients : A UK-wide surveillance study. Lancet Psychiatry. 2020 ; 7 : 875-82.
PubMed
10) Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19 : The ALBA COVID registry. Neurology. 2020 ; 95 : e1060-70.
 
11) Portela-Sanchez S, Sanchez-Soblechero A, Melgarejo Otalora PJ, et al. Neuroloical complications of COVID-19 in hospitalized patients : The registry of a neurology department in the first wave of the pandemic. Eur J Neurol. 2021 ; 28 : 3339-47.
 
12) https://covid-registry.ncgm.go.jp
PubMed
13) Matsunaga N, Hayakawa K, Terada M, et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan : Report of the COVID-19 Registry Japan. Clin Infect Dis. 2021 ; 73 : e3677-e3689.
PubMed
14) Terada M, Ohtsu H, Saito S, et al. Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021 ; 11 : e047007.
 
15) Roman GC, Spencer PS, Reis J, et al. The neurology of COVID-19 revisited : A proposal from the environmental neurology special group of the world federation of neurology to implement international neurological registries. J Neurol Sci. 2020 ; 414 : 116884.
 
16) Beghi E, Helbok R, Crean M, et al. The European academy of neurology COVID-19 registry (ENERGY) : An international instrument for surveillance of neurological complications in patients with COVID-19. Eur J Neurol. 2021 ; 28 : 3303-23.
PubMed
17) https://www.ean.org/research/registries-surveys/neuro-covid-registry
 
P.99 掲載の参考文献
1) Ishiyama H, Ishii J, Yoshimura H, et al. Neurological manifestations and long-term sequelae in hospitalized patients with COVID-19. Intern Med. 2021 ; 60 : 3559-67.
PubMed
2) Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 ; 77 : 683-90.
 
3) Kremer S, Lersy F, de Seze J, et al. Brain MRI findings in severe COVID-19 : A retrospective observational study. Radiology. 2020 ; 297 : E242-51.
PubMed
4) Agarwal S, Jain R, Dogra S, et al. Cerebral microbleeds and leukoencephalopathy in critically ill patients with COVID-19. Stroke. 2020 ; 51 : 2649-55.
PubMed
5) Fanou EM, Coutinho JM, Shannon P, et al. Critical illness-associated cerebral microbleeds. Stroke. 2017 ; 48 : 1085-7.
PubMed
6) Wan D, Du T, Hong W, et al. Neurological complications and infection mechanism of SARS-COV-2. Signal Transduct Target Ther. 2021 ; 6 : 406.
PubMed
7) Tankisi H, Tankisi A, Harbo T, et al. Critical illness myopathy as a consequence of Covid-19 infection. Clin Neurophysiol. 2020 ; 131 : 1931-2.
PubMed
8) Cabanes-Martinez L, Villadoniga M, Gonzalez-Rodriguez L, et al. Neuromuscular involvement in COVID-19 critically ill patients. Clin Neurophysiol. 2020 ; 131 : 2809-16.
PubMed
9) Frithiof R, Rostami E, Kumlien E, et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients : A prospective study. Clin Neurophysiol. 2021 ; 132 : 1733-40.
PubMed
P.107 掲載の参考文献
1) Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 ; 395 : 497-506.
 
2) Tan YP, Tan BY, Pan J, et al. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. J Clin Virol. 2020 ; 127 : 104353.
 
3) Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 ; 382 : 1708-20.
 
4) Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : A descriptive study. Lancet. 2020 ; 395 : 507-13.
 
5) Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China : A systematic review and meta-analysis. J Infect. 2020 ; S0163-4453 : 30170-5.
 
6) Lovato A, de Filippis C. Clinical presentation of COVID-19 : A systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020 : 145561320920762.
 
7) British Association of Otorhinolaryngology-Head and Neck Surgery. Loss of sense of smell as marker of COVID-19 infection [Internet] ; c2020 [Cited 2020 Apr 17].
 
8) The Centers for Disease Control and Prevention. Symptoms of Coronavirus [Internet] ; c2020 [Cited 2020 Apr 27].
 
9) Suzuki M, Saito K, Min WP, et al. Identification of viruses in patients with postviral olfactory dysfunction. Laryngoscope. 2007 ; 117 : 272-7.
PubMed
10) Beltran-Corbellini A, Chico-Garcia JL, Martinez-Poles J, et al. Acute-onset smell and taste disorders in the context of Covid-19 : A pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 ; 27 : 1738-41.
 
11) Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19) : a multicenter European study. Eur Arch Otorhinolaryngol. 2020 ; 1-11.
 
12) Moein ST, Hashemian SMR, Mansourafshar B, et al. Smell dysfunction : A biomarker for COVID-19. Int Forum Allergy Rhinol. 2020 ; 10 : 944-50.
 
13) Qiu J, Yang X, Liu L, et al. Prevalence and prognosis of otorhinolaryngological symptoms in patients with COVID-19 : a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2022 ; 279 : 49-60.
PubMed
14) Ibekwe TS, Fasunla AJ, Orimadegun AE. Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19. OTO Open. 2020 ; 4 : 2473974X20957975.
PubMed
15) Menni C, Valdes A, Freydin MB, et al. Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection. medRxiv. 2020 : 2020. 04. 05. 20048421.
 
16) Levinson R, Elbaz M, Ben-Ami R, et al. Anosmia and dysgeusia in patients with mild SARS-CoV-2 infection. medRxiv. 2020 : 2020. 04. 11. 20055483.
 
17) Benezit F, Le Turnier P, Declerck C, et al. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. Lancet Infect Dis. 2020 ; 20 : 1014-5.
 
18) Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients : a cross-sectional study. Clin Infect Dis. 2020 ; 71 : 889-90.
PubMed
19) Mahyuddin AP, Kanneganti A, Wong JJL, et al. Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2s. Prenatal Diagnosis. 2020 ; 40 : 1655-70.
PubMed
20) Matsuyama S, Ujike M, Morikawa S, et al. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci. 2005 ; 102 : 12543-7.
PubMed
21) 宮内浩典. エンベロープウイルスの宿主細胞への侵入過程. ウイルス. 2009 ; 59 : 205-14.
 
22) 松山州徳. プロテアーゼ依存的なコロナウイルス細胞侵入. ウイルス. 2011 ; 61 : 109-16.
 
23) Ueha R, Kondo K, Kagoya R, et al. ACE2, TMPRSS2, and Furin expression in the nose and olfactory bulb in mice and humans. Rhinology. 2021 ; 59 : 105-9.
PubMed
24) Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020 ; 251 : 228-48.
PubMed
25) Darbani B. The expression and polymorphism of entry machinery for COVID-19 in human : Juxtaposing population groups, gender, and different tissues. Int J Environ Res Public Health. 2020 ; 17 : 3433.
 
26) Butowt R, Bilinska K. SARS-CoV-2 : Olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020 ; 11 : 1200-3.
PubMed
27) Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 ; 12.
PubMed
28) Vaira LA, Salzano G, Deiana G, et al. Common Findings in COVID-19 Patients. Laryngoscope. 2020 ; 130 : 1787.
PubMed
29) Brann D, Tsukahara T, Weinreb C, et al. Non-neural expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. BioRxiv. 2020 [cited 2020 Apr 30].
 
30) Yao L, Yi X, Pinto JM, et al. Olfactory cortex and olfactory bulb volume alterations in patients with post-infectious olfactory loss. Brain Imaging Behav. 2018 ; 12 : 1355-62.
PubMed
31) Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017 ; 54 : 1-30.
PubMed
32) Youngentob SL, Schwob JE, Saha S, et al. Functional consequences following infection of the olfactory system by intranasal infusion of the olfactory bulb line variant (OBLV) of mouse hepatitis strain JHM. Chem Senses. 2001 ; 26 : 953-63.
PubMed
33) Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. Cell Host Microbe. 2013 ; 13 : 379-93.
PubMed
34) Anthony N van den Pol. Viral infections in the developing and mature brain. Trends Neurosci. 2006 ; 29 : 398-406.
PubMed
35) Sakaguchi W, Kubota N, Shimizu T, et al. Existence of SARS-CoV-2 entry molecules in the oral cavity. Int J Mol Sci. 2020 ; 21 : 6000.
 
36) Kanjanaumporn J, Aeumjaturapat S, Snidvongs K, et al. Smell and taste dysfunction in patients with SARS-CoV-2 infection : A review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pac J Allergy Immunol. 2020 ; 38 : 69-77.
PubMed
37) Scangas GA, Bleier BS. Anosmia : Differential diagnosis, evaluation, and management. Am J Rhinol Allergy. 2017 ; 31 : 3-7.
PubMed
38) Bousquet J, Akdis C, Jutel M, et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients : An ARIA-EAACI statement. Allergy. 2020 ; 75 : 2440-4.
PubMed
39) 小川恵子. 嗅覚・味覚障害の漢方療法. MB ENT. 2020 ; 251 : 67-76.
 
40) Hummel T, Rissom K, Reden J, et al. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009 ; 119 : 496-9.
PubMed
41) Altundag A, Cayonu M, Kayabasoglu G, et al. Modified olfactory training in patients with postinfectious olfactory loss. Laryngoscope. 2015 ; 125 : 1763-6.
PubMed
42) Konstantinidis I, Tsakiropoulou E, Constantinidis J. Long term effects of olfactory training in patients with post-infectious olfactory loss. Rhinology. 2016 ; 54 : 170-5.
PubMed
P.117 掲載の参考文献
1) Albers MW, Tabert MH, Devanand DP. Olfactory dysfunction as a predictor of neurodegenerative disease. Curr. Neurol Neurosci Rep. 2006 ; 6 : 379-86.
PubMed
2) Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012 ; 8 : 329-39.
PubMed
3) Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci USA. 2020 ; 117 : 16587-95.
PubMed
4) Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfaory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020 ; 5801 : eabc5801.
 
5) Fodoulian L, Tuberosa J, Rossier D, et al. SARS-CoV-2 receptors and entry genes are expressed in the human olfactory neuroepithelium and brain. iScience. 2020 ; 23 : 101839.
PubMed
6) Khan M, Yoo S-J, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021 ; 184 : 5932-49.e15.
 
7) Bryche B, St Albin A, Murri S, et al. Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav Immun. 2020 ; S0889-1591 : 31358-1.
 
8) Urata S, Maruyama J, Kishimoto-Urata M, et al. Regeneration profiles of olfactory epithelium after SARS-CoV-2 infection in golden Syrian hamsters. ACS Chem Neurosci. 2021 ; 12 : 589-95.
PubMed
9) de Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021 ; 13 : eabf8396.
PubMed
10) Zazhytska M, Kodra A, Hoagland DA, et al. Non-cell autonomous disruption of nuclear architecture as a potential cause of COVID-19 induced anosmia. Cell. 2022 ; 185 ; 1052-64. e12.
 
11) Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany : a post-mortem case series. Lancet Neurol. 2020 ; 19 : 919-29.
 
12) Kishimoto-Urata M, Urata S, Kagoya R, et al. Prolonged and extended impacts of SARS-CoV-2 on the olfactory neurocircuit. Sci Rep. 2022 ; 12 : 5728.
PubMed
13) Ikeda K, Sakurada T, Suzaki Y. Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease. Rhinology. 1995 ; 33, 162-5.
PubMed
14) Henkin R, Schecter PJ, Friedewald WT, et al. A double blind study of the effects of zinc sulfate on taste and smell dysfunction. Am J Med Sci. 1976 ; 272 : 285-99.
PubMed
15) 山田健太郎, 志賀英明, 能田拓也, 他. 嗅神経性嗅覚障害の病態解明と治療への応用. 日本鼻科学会会誌. 2018 ; 57 : 83-6.
 
16) Geisler K, Reimann H, Gudziol H, et al. Olfactory training for patients with olfactory loss after upper respiratory tract infections. Eur Arch Oto-Rhino-Laryngology. 2014 ; 271 : 1557-62.
 
17) Abdelalim AA, Mohamady AA, Elsayed RA, et al. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients : a randomized controlled trial. Am J Otolaryngol. 2021 ; 42 : 102884.
PubMed
18) Denis F, Septans AL, Periers L, et al. Olfactory training and visual stimulation assisted by a web application for patients with persistent olfactory dysfunction after SARS-CoV-2 infection : Observational study. J Med Internet Res. 2021 ; 23 : e29583.
PubMed
19) Kanjanaumporn J, Aeumjaturapat S, Snidvongs K, et al. Smell and taste dysfunction in patients with SARS-CoV-2 infection : A review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pacific J allergy Immunol. 2020 ; 38 : 69-77.
 
20) Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020 ; 583 : 290-5.
PubMed
21) Gottlieb RL, Nirula A, Chen P, Boscia J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 : a randomized clinical trial. JAMA. 2021 ; 325 : 632-44.
PubMed
22) Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021 ; 384 : 238-51.
PubMed
23) Reden J, Lill K, Zahnert T, et al. Olfactory function in patients with postinfectious and posttraumatic smell disorders before and after treatment with vitamin A : A double-blind, placebo-controlled, randomized clinical trial. Laryngoscope. 2012 ; 122 : 1906-9.
PubMed
24) de Vries RD, Schmitz KS, Bovier FT, et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science. 2021 ; 371 : 1379-82.
PubMed
P.127 掲載の参考文献
1) Yao Q, Wang P, Wang X, et al. A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020 ; 130 : 390-9.
 
2) Zayet S, Kadiane-Oussou NJ, Lepiller Q, et al. Clinical features of COVID-19 and influenza : a comparative study on Nord Franche-Comte cluster. Microbes Infect. 2020 ; 22 : 481-8.
PubMed
3) Dos Anjos de Paula RC, de Maria Frota Vasconcelos T, da Costa FBS, et al. Characterization of headache in COVID-19 : A retrospective multicenter study. Mol Neurobiol. 2021 ; 58 : 4487-94.
PubMed
4) Straburzynski M, Nowaczewska M, Budrewicz S, et al. COVID-19-related headache and sinonasal inflammation : A longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection. Cephalalgia. 2021 ; 42 : 218-28.
PubMed
5) Caronna E, Ballve A, Llaurado A, et al. Headache : A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020 ; 40 : 1410-21.
PubMed
6) Garcia-Azorin D, Sierra A, Trigo J, et al. Frequency and phenotype of headache in covid-19 : A study of 2194 patients. Sci Rep. 2021 ; 11 : 14674.
 
7) Uygun O, Ertas M, Ekizoglu E, et al. Headache characteristics in COVID-19 pandemic-a survey study. J Headache Pain. 2020 ; 21 : 121.
PubMed
8) Mutiawati E, Syahrul S, Fahriani M, et al. Global prevalence and pathogenesis of headache in COVID-19 : A systematic review and meta-analysis. F1000Res. 2020 ; 9 : 1316.
PubMed
9) Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel coronavirus infection (COVID-19) in humans : A scoping review and meta-analysis. J Clin Med. 2020 ; 9 : E941.
 
10) Bobker SM, Robbins MS. Residents and fellows : Opinions in headache education. COVID-19 and headache : A primer for trinees. Headache. 2020 ; 60 : 1806-11.
 
11) Bobker SM, Robbins MS. Virtual issue : COVID-19 and headache. Headache. 2021 ; 61 : 412-3.
PubMed
P.140 掲載の参考文献
1) 和田邦泰, 橋本洋一郎, 中島誠, 他. COVID-19 流行と脳卒中. 臨床神経. 2020 ; 60 : 822-39.
 
2) Khosravani H, Rajendram P, Notario L, et al. Protected code stroke : Hyperacute stroke management during the coronavirus disease 2019 (COVID-19) pandemic. Stroke. 2020 ; 51 : 1891-5.
PubMed
3) 平野照之, 天野達雄, 早川幹人, 他. COVID-19 対応 脳卒中プロトコル (日本脳卒中学会版Protected Code Stroke : JSS-PCS). 脳卒中. 2020 ; 42 : 315-43.
 
4) Shahjouei S, Tsivgoulis G, Farahmand G, et al. SARS-CoV-2 and stroke characteristics : A report from the Multinational COVID-19 Stroke Study Group. Stroke. 2021 ; 52 : e117-30.
 
5) Ross Russell AL, Hardwick M, Jeyanantham A, et al. Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19 : A UK-wide cross-sectional surveillance study. Brain Commun. 2021 ; 3 : fcab168.
PubMed
6) Cheruiyot I, Sehmi P, Ominde B, et al. Intracranial hemorrhage in coronavirus disease 2019 (COVID-19) patients. Neurol Sci. 2021 ; 42 : 25-33.
PubMed
7) Beyrouti R, Best JG, Chandratheva A, et al. Characteristics of intracerebral haemorrhage associated with COVID-19 : A systematic review and pooled analysis of individual patient and aggregate data. J Neurol. 2021 ; 268 : 3105-15.
 
8) Lawton MT, Alimohammadi E, Bagheri SR, et al. Coronavirus disease 2019 (COVID-19) can predispose young to intracerebral hemorrhage : A retrospective observational study. BMC Neurol. 2021 ; 21 : 83.
 
9) Qureshi AI, Baskett WI, Huang W, et al. Intracerebral hemorrhage and coronavirus disease 2019 in a cohort of 282,718 hospitalized patients. Neurocrit Care. 2022 ; 36 : 259-65.
 
10) Tu TM, Goh C, Tan YK, et al. Cerebral venous thrombosis in patients with COVID-19 infection : A case series and systematic review. J Stroke Cerebro vasc Dis. 2020 ; 29 : 105379.
 
11) Baldini T, Asioli GM, Romoli M, et al. Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection : A systematic review and meta-analysis. Eur J Neurol. 2021 ; 28 : 3478-90.
PubMed
12) Motolese F, Ferrante M, Rossi M, et al. Posterior reversible encephalopathy syndrome and brain haemorrhage as COVID-19 complication : A review of the available literature. J Neurol. 2021 ; 268 : 4407-14.
PubMed
13) Arandela K, Samudrala S, Abdalkader M, et al. Reversible cerebral vasoconstriction syndrome in patients with coronavirus disease : A multicenter case series. J Stroke Cerebrovasc Dis. 2021 ; 30 : 106118.
 
14) Srinivasan A, Wilson BC, Bear M, et al. Intracerebral hemorrhage and reversible cerebral vasoconstriction syndrome in a patient with COVID-19. Cureus. 2021 ; 13 : e17408.
 
15) Siddiqui J, Bala F, Sciacca S, et al. COVID-19 stroke apical lung examination study : A diagnostic and prognostic imaging biomarker in suspected acute stroke. AJNR Am J Neuroradiol. 2021 ; 42 : 138-43.
PubMed
16) Esenwa C, Lee JA, Nisar T, et al. Utility of apical lung assessment on computed tomography angiography as a COVID-19 screen in acute stroke. Stroke. 2020 ; 51 : 3765-9.
PubMed
17) Cagnazzo F, Piotin M, Escalard S, et al. European multicenter study of ET-COVID-19. Stroke. 2021 ; 52 : 31-9.
PubMed
18) Carneiro T, Dashkoff J, Leung LY, et al. Intravenous tPA for acute ischemic stroke in patients with COVID-19. J Stroke Cerebrovasc Dis. 2020 ; 29 : 105201.
PubMed
19) Gioia LC, Poppe AY, Laroche R, et al. Streamlined poststroke treatment order sets during the SARS-CoV-2 pandemic : Simplifying while not compromising care. Stroke. 2020 ; 51 : 3115-8.
 
20) Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Higher mortality of ischaemic stroke patients hospitalized with COVID-19 compared to historical controls. Cerebrovasc Dis. 2021 ; 50 : 326-31.
PubMed
21) Calmettes J, Peres R, Goncalves B, et al. Clinical outcome of acute ischemic strokes in patients with COVID-19. Cerebrovasc Dis. 2021 ; 50 : 412-9.
PubMed
22) Marti-Fabregas J, Guisado-Alonso D, Delgado-Mederos R, et al. Impact of COVID-19 infection on the outcome of patients with ischemic stroke. Stroke. 2021 ; 52 : 3908-17.
PubMed
23) Katz JM, Libman RB, Wang JJ, et al. Cerebrovascular complications of COVID-19. Stroke. 2020 ; 51 : e227-31.
PubMed
24) Chachkhiani D, Soliman MY, Barua D, et al. Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization. Clin Neurol Neurosurg. 2020 ; 197 : 106173.
 
25) Cummings C, Almallouhi E, Al Kasab S, et al. Blacks are less likely to present with strokes during the COVID-19 pandemic : Observations from the buckle of the stroke belt. Stroke. 2020 ; 51 : 3107-11.
PubMed
26) Perry RJ, Smith CJ, Roffe C, et al. Characteristics and outcomes of COVID-19 associated stroke : A UK multicentre case-control study. J Neurol Neurosurg Psychiatry. 2021 ; 92 : 242-8.
PubMed
27) Esenwa C, Unda SR, Altschul DJ, et al. The effect of race on composite thrombotic events in patients with COVID-19. Thromb Res. 2021 ; 199 : 10-3.
PubMed
28) Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza : a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021 ; 9 : 251-9.
PubMed
29) Smilowitz NR, Subashchandran V, Yuriditsky E, et al. Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19. Am Heart J. 2021 ; 231 : 93-5.
PubMed
30) Bekelis K, Missios S, Ahmad J, et al. Ischemic stroke occurs less frequently in patients with COVID-19 : A multicenter cross-sectional study. Stroke. 2020 ; 51 : 3570-6.
PubMed
31) Zhang S, Zhang J, Wang C, et al. COVID19 and ischemic stroke : Mechanisms of hypercoagulability (Review). Int J Mol Med. 2021 ; 47 : 21.
PubMed
P.149 掲載の参考文献
1) Casez O, Willaume G, Grand S, et al. Teaching neuroImages : SARS-CoV-2-related encephalitis : MRI pattern of olfactory tract involvement. Neurology. 2021 ; 96 : e645-6.
PubMed
2) Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany : A post-mortem case series. Lancet Neurol. 2020 ; 19 : 919-29.
 
3) Thakur KT, Miller EH, Glendinning MD, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021 ; 144 : 2696-708.
PubMed
4) Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021 ; 184 : 5932-49.e15.
 
5) Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021 ; 24 : 168-75.
PubMed
6) Wenzel J, Lampe J, Muller-Fielitz H, et al. The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci. 2021 ; 24 : 1522-33.
PubMed
7) Perrin P, Collongues N, Baloglu S, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021 ; 28 : 248-58.
PubMed
8) McAlpine LS, Zubair AS, Maran I, et al. Ischemic Stroke, Inflammation, and Endotheliopathy in COVID-19 Patients. Stroke. 2021 ; 52 : e233-8.
PubMed
9) Iba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020 ; 24 : 360.
PubMed
10) Espindola OM, Gomes YCP, Brandao CO, et al. Inflammatory Cytokine Patterns Associated with Neurological Diseases in Coronavirus Disease 2019. Ann Neurol. 2021 ; 89 : 1041-5.
PubMed
11) Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021 ; 595 : 283-8.
PubMed
12) Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020 ; 94 : 55-8.
PubMed
13) Bernard-Valnet R, Pizzarotti B, Anichini A, et al. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. Eur J Neurol. 2020 ; 27 : e43-4.
PubMed
14) Pilotto A, Odolini S, Masciocchi S, et al. Steroid-Responsive Encephalitis in Coronavirus Disease 2019. Ann Neurol. 2020 ; 88 : 423-7.
PubMed
15) Bodro M, Compta Y, Llanso L, et al. "Hospital Clinic Infecto-COVID-19" and "Hospital Clinic Neuro-COVID-19" groups. Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e821.
 
16) Huang H, Eichelberger H, Chan M, et al. Pearls & Oy-sters : Leukoencephalopathy in critically ill patients with COVID-19. Neurology. 2020 ; 95 : 753-7.
PubMed
17) Pugin D, Vargas MI, Thieffry C, et al. COVID-19-related encephalopathy responsive to high-dose glucocorticoids. Neurology. 2020 ; 95 : 543-6.
PubMed
18) Alexopoulos H, Magira E, Bitzogli K, et al. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome : Studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e893.
PubMed
19) Kudo T, Hayashi Y, Kunieda K, et al. Persistent intrathecal interleukin-8 production in a patient with SARS-CoV-2-related encephalopathy presenting aphasia : A case report. BMC Neurol. 2021 ; 21 : 426.
 
20) Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 ; 15 : 391-404.
PubMed
21) Cao A, Rohaut B, Le Guennec L, et al. Severe COVID-19-related encephalitis can respond to immunotherapy. Brain. 2020 ; 143 : e102.
PubMed
22) Elkady A, Rabinstein AA. Acute necrotizing encephalopathy and myocarditis in a young patient with COVID-19. Neurology. June 4, 2020. doi.org/10.1212/NXI.0000000000000801
 
23) Virhammar J, Kumlien E, Fallmar D, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020 ; 95 : 445-9.
PubMed
24) Morvan AC, Kerambrun H. Fatal necrotizing encephalitis associated with COVID-19. Neurol Clin Pract. 2021 ; 11 : e214-5.
PubMed
25) Delamarre L, Gollion C, Grouteau G, et al. COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. J Neurol Neurosurg Psychiatry. 2020 ; 91 : 1004-6.
PubMed
26) Parsons T, Banks S, Bae C, et al. COVID-19-associated acute disseminated encephalomyelitis (ADEM). J Neurol. 2020 ; 267 : 2799-802.
 
27) Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings. Brain. 2020 ; 143 : 3104-20.
PubMed
28) Karapanayiotides T, Geka E, Prassopoulos P, et al. Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis : a lurking catastrophe? Brain. 2020 ; 143 : e100.
PubMed
29) Hayashi M, Sahashi Y, Baba Y, et al. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci. 2020 ; 415 : 116941.
PubMed
30) Edjlali M, Le Gal A, Louvet M, et al. Teaching neuroImages : Cytotoxic lesions of the corpus callosum in encephalopathic patients with COVID-19. Neurology. 2020 ; 95 : 1021-2.
PubMed
31) Abdel-Mannan O, Eyre M, Lobel U, et al. Neurologic and radiographic findings associated with COVID-19 infection in children. JAMA Neurol. 2020 ; 77 : 1440-5.
PubMed
32) Kishfy L, Casasola M, Banankhah P, et al. Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19. J Neurol Sci. 2020 ; 414 : 116943.
PubMed
33) Wijers A, Hochstenbach L, Tissingh G. Telemonitoring via questionnaires reduces outpatient healthcare consumption in Parkinson's disease. Mov Disord Clin Pract. 2021 ; 8 : 1075-82.
PubMed
34) Shah PB, Desai SD. Opsoclonus myoclonus ataxia syndrome in the setting of COVID-19 infection. Neurology. 2021 ; 96 : 33.
PubMed
35) Foucard C, San-Galli A, Tarrano C, et al. Acute cerebellar ataxia and myoclonus with or without opsoclonus : A para-infectious syndrome associated with COVID-19. Eur J Neurol. 2021 ; 28 : 3533-6.
PubMed
36) Pascual-Goni E, Fortea J, Martinez-Domeno A, et al. COVID-19-associated ophthalmoparesis and hypothalamic involvement. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e823.
PubMed
37) Alberola-Amores FJ, Valdeolivas-Urbelz E, Torregrosa-Ortiz M, et al. Meningitis due to cerebrospinal fluid leak after nasal swab testing for COVID-19. Eur J Neurol. 2021 ; 28 : e91-2.
PubMed
38) Erburu-Iriarte M, Rodrigo-Armenteros P, Oyarzun-Irazu I, et al. Chronic severe methanol intoxication after repeated mask cleansing due to fear of COVID-19 : A new risk of coronaphobia. Eur J Neurol. 2021 ; 28 : 3448-51.
PubMed
39) Zuhorn F, Graf T, Klingebiel R, et al. Postvaccinal encephalitis after ChAdOx1 nCov-19. Ann Neurol. 2021 ; 90 : 506-11.
PubMed
P.158 掲載の参考文献
1) Manzano GS, McEntire CRS, Martinez-Lage M, et al. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19 : Systematic review and meta-synthesis. Neurol Neuroimmunol Neuroinflamm. 2021 ; 8 : e1080.
PubMed
2) Palao M, Fernandez-Diaz E, Gracia-Gil J, et al. Multiple sclerosis following SARS-CoV-2 infection. J Neuroimmunol. 2020 ; 45 : 102377.
 
3) Sepulveda M, Llufriu S, Martinez-Hernandez E, et al. incidence and impact of COVID-19 in MS. A survey from a Barcelona MS Unit. Neurol Neuroimmunol Neuroinflamm. 2021 ; 8 : e954.
 
4) Parrotta E, Kister L, Charvet L, et al. COVID-19 outcomes in MS. Neurol Neuroimmunol Neuroinflamm. 2020 ; 7 : e835.
 
5) Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 202178 : 1-10.
 
6) Garjani A, Middleton RM, Nicholas R, et al. Recovery from COVID-19 in multiple sclerosis : A prospective and longitudinal cohort study of the united king dom multiple sclerosis register. Neurol Neuroimmunol Neuroinflamm. 2021 ; 30 : e1118.
 
7) Gimenez-Llort L, Martin-Gonzalez JJ, Maurel S. Secondary impacts of COVID-19 in fatigue, self-compassion, physical and mental health of people with multiple sclerosis and caregivers : the Teruel study. Brain Sci. 2021 ; 11 : 1233.
PubMed
8) Fragoso RD, Pacheco FAS, Silveira GL, et al. COVID-19 in a temporal relation to the onset of multiple sclerosis. Mult Scler Relat Disord. 2021 ; 50 : 102863.
 
9) Tomczak A, Han MH. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorders ; A pilot study. Mult Scler. 2020 ; 45 : 102347.
PubMed
10) Apostolos-Pereira SL, Ferreira LC, Boanventura M. Clinical features of COVID-19 on patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2021 ; 8 : e1060.
 
11) Stastna D, Menkyova I, Drahota J, et al. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19 : A pandemic year in Czechia. Mult Scler Relat Disord. 2021 ; 54 : 103104.
 
12) Newsome SD, Cross AH, Fox RJ, et al. COVID-19 in patients with neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody disease in North America. From the COViMS Registry. Neurol Neuroimmunol Neuroinflamm. 2021 ; 8 : e1057.
PubMed
13) Ghosh R, De K, Roy D, et al. A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection. J Neuroimmunol. 2021 ; 350 : 577439.
 
14) Kaseka ML, Ly M, Yea C, et al. Impact of COVID-19 public health measures on myelin oligodendrocyte glycoprotein IgG-associated disorders in children. Mult Scler Relat Disord. 2021 ; 56 : 103286.
PubMed
15) Roman GC, Gracia F, Torres A, et al. Acute transverse myelitis (ATM) : Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021 ; 12 : 653786.
PubMed
16) Khayat-Khoei M, Bhattacharyya S, Katz J, et al. COVID-19 mRNA vaccination leading to CNS inflammation : a case series. J Neurol. 2022 ; 269 : 1093-106.
 
17) Mumoli L, Vescio V, Pirritano D, et al. ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination. Neurol Sci. 2022 ; 43 : 763-6.
PubMed
18) Dams L, Kraemer M, Becker J. MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination. Mult Scler. 2021 ; 13524585211057512.
PubMed
19) Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 Vaccine respons in people with multiple sclerosis. Ann Neurol. 2022 ; 91 : 89-100.
 
P.165 掲載の参考文献
1) Restivo DA, Centonze D, Alesina A, et al. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020 ; 173 : 1027-8.
PubMed
2) Sriwastava S, Tandon M, Kataria S, et al. New onset of ocular myasthenia gravis in a patient with COVID-19 : A novel case report and literature review. J Neurol. 2021 ; 268 : 2690-6.
 
3) Assini A, Gandoglia I, Damato V, et al. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection. Eur J Neurol. 2021.
PubMed
4) Anand P, Slama MCC, Kaku M, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020 ; 62 : 254-8.
PubMed
5) Businaro P, Vaghi G, Marchioni E, et al. COVID-19 in patients with myasthenia gravis : Epidemiology and disease course. Muscle Nerve. 2021 ; 64 : 206-11.
PubMed
6) Camelo-Filho AE, Silva AMS, Estephan EP, et al. Myasthenia Gravis and COVID-19 : Clinical characteristics and outcomes. Front Neurol. 2020 ; 11 : 1053.
PubMed
7) Galassi G, Marchioni A. Myasthenia gravis at the crossroad of COVID-19 : Focus on immunological and respiratory interplay. Acta Neurol Belg. 2021 ; 121 : 633-42.
PubMed
8) Jacob S, Muppidi S, Guidon A, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020 ; 412 : 116803.
PubMed
9) Muppidi S, Guptill JT, Jacob S, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020 ; 19 : 970-1.
 
10) https://myasthenia.org/Professionals/Resources-for-Professionals/CARE-MG, February 12, 2022
 
P.172 掲載の参考文献
1) Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 ; 77 : 683-90.
 
2) Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19 : The ALBA COVID registry. Neurology. 2020 ; 95 : e1060-70.
 
3) Karadas O, Ozturk B, Sonkaya AR. A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurol Sci. 2020 ; 41 : 1991-5.
PubMed
4) Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020 ; 7 : 2221-30.
PubMed
5) Moro E, Priori A, Beghi E, et al. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur J Neurol. 2020 ; 27 : 1727-37.
PubMed
6) Flores-Silva FD, Garcia-Grimshaw M, Valdes-Ferrer SI, et al. Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City. PLoS One. 2021 ; 16 : e0247433.
PubMed
7) Garcia-Azorin D, Abildua MJA, Aguirre MEE, et al. Neurological presentations of COVID-19 : Findings from the Spanish Society of Neurology neuro-COVID-19 registry. J Neurol Sci. 2021 ; 423 : 117283.
PubMed
8) Garcia S, Cuatepotzo-Burgos FM, Toledo-Lozano CG, et al. Neurological manifestations and outcomes in a retrospective cohort of Mexican inpatients with SARS-CoV-2 pneumonia : Design of a risk profile. Healthcare (Basel). 2021 ; 9 : 1501.
 
9) Brandao PRP, Grippe TC, Pereira DA, et al. New-onset movement disorders associated with COVID-19. Tremor Other Hyperkinet Mov (NY). 2021 ; 11 : 26.
 
10) Borroni B, Gazzina S, Dono F, et al. Diaphragmatic myoclonus due to SARS-CoV-2 infection. Neurol Sci. 2020 ; 41 : 3471-4.
PubMed
11) El Otmani H, Moutaouakil F, Ouazzani M, et al. Isolated generalized myoclonus immune-mediated by SARS-CoV-2 : an illustrative videotaped case. Neurol Sci. 2021 ; 42 : 3411-3.
PubMed
12) Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ, et al. Reversible myoclonus-ataxia as a postinfectious manifestation of COVID-19. Mov Disord Clin Pract. 2020 ; 7 : 977-9.
PubMed
13) Khoo A, McLoughlin B, Cheema S, et al. Postinfectious brainstem encephalitis associated with SARS-CoV-2. J Neurol Neurosurg Psychiatry. 2020 ; 91 : 1013-4.
PubMed
14) Anand P, Zakaria A, Benameur K, et al. Myoclonus in patients with coronavirus disease 2019 : A multicenter case series. Crit Care Med. 2020 ; 48 : 1664-9.
PubMed
15) Cuhna P, Herlin B, Vassilev K, et al. Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection. Eur J Neurol. 2020 ; 27 : e88-90.
PubMed
16) Ros-Castello V, Quereda C, Lopez-Sendon J, et al. Post-hypoxic myoclonus after COVID-19 infection recovery. Mov Disord Clin Pract. 2020 ; 7 : 983-4.
 
17) Torrealba-Acosta G, Martin JC, Huttenbach Y, et al. Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Rep. 2021 ; 14 : e243173.
 
18) Emamikhah M, Babadi M, Mehrabani M, et al. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19 : case series and review of literature. J Neurovirol. 2021 ; 27 : 26-34.
PubMed
19) Foucard C, San-Galli A, Tarrano C, et al. Acute cerebellar ataxia and myoclonus with or without opsoclonus : a para-infectious syndrome associated with COVID-19. Eur J Neurol. 2021 ; 28 : 3533-6.
PubMed
20) Oh SY, Kim JS, Dieterich M. Update on opsoclonus-myoclonus syndrome in adults. J Neurol. 2019 ; 266 : 1541-8.
PubMed
21) Nelson JL, Blume GM, Bansal SK, et al. Postinfectious SARS-CoV-2 opsoclonus-myoclonus-ataxia syndrome. J Neuroophthalmol. 2021 Dec 30.
 
22) Urrea-Mendoza E, Okafor K, Ravindran S, et al. Opsoclonus-myoclonus-ataxia syndrome (OMAS) associated with SARS-CoV-2 infection : Post-infectious neurological complication with benign prognosis. Tremor Other Hyperkinet Mov (NY). 2021 ; 11 : 7.
 
23) Mendez-Guerrero A, Laespada-Garcia MI, Gomez-Grande A, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. 2020 ; 95 : e2109-18.
PubMed
24) Faber I, Brandao PRP, Menegatti F, et al. Coronavirus disease 2019 and parkinsonism : A non-post-encephalitic Case. Mov Disord. 2020 ; 35 : 1721-2.
PubMed
25) Cohen ME, Eichel R, Steiner-Birmanns B, et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurol. 2020 ; 19 : 804-5.
 
26) Pilotto A, Masciocchi S, Volonghi I, et al. Clinical presentation and outcomes of severe acute respiratory syndrome coronavirus 2-related encephalitis : The ENCOVID multicenter study. J Infect Dis. 2021 ; 223 : 28-37.
PubMed
27) Ray STJ, Abdel-Mannan O, Sa M, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK : a prospective national cohort study. Lancet Child Adolesc Health. 2021 ; 5 : 631-41.
 
28) Hassan M, Syed F, Ali L, et al. Chorea as a presentation of SARS-CoV-2 encephalitis : A clinical case report. J Mov Disord. 2021 ; 14 : 245-7.
 
29) Cotta Ramusino M, Perini G, Corrao G, et al. Sars-Cov-2 in a patient with acute chorea : Innocent bystander or unexpected actor? Mov Disord Clin Pract. 2021 ; 8 : 950-3.
PubMed
30) Yuksel MF, Yildirim M, Bektas O, et al. A Sydenham chorea attack associated with COVID-19 infection. Brain Behav Immun Health. 2021 ; 13 : 100222.
PubMed
31) Hoelscher C, Sweid A, Ghosh R, et al. Cerebral deep venous thrombosis and COVID-19 : case report. J Neurosurg. 2020 : 1-4.
PubMed
32) de Almeida JN Jr, Francisco EC, Hagen F, et al. Emergence of Candida auris in Brazil in a COVID-19 intensive care unit. J Fungi (Basel). 2021 ; 7 : 220.
 
33) Ghosh R, Dubey S, Roy D, et al. Choreo-ballistic movements heralding COVID-19 induced diabetic ketoacidosis. Diabetes Metab Syndr. 2021 ; 15 : 913-7.
PubMed
34) Matar E, Manser D, Spies JM, et al. Acute Hemichorea-hemiballismus following COVID-19 (AZD1222) vaccination. Mov Disord. 2021 ; 36 : 2714-5.
PubMed
35) Lo Monaco MR, Bentivoglio AR, Fusco D, et al. Subacute onset dystonia in a woman affected by Parkinson's disease following SARS-COV-2 infection. Clin Park Relat Disord. 2021 ; 4 : 100082.
 
36) Xu Y, Surface M, Chan AK, et al. COVID-19 manifestations in people with Parkinson's disease : a USA cohort. J Neurol. 2022 ; 269 : 1107-13.
PubMed
37) Erro R, Buonomo AR, Barone P, et al. Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson's disease. Mov Disord. 2021 ; 36 : 2219.
PubMed
38) Ishiyama H, Ishii J, Yoshimura H, et al. Neurological manifestations and long-term sequelae in hospitalized patients with COVID-19. Intern Med. 2021 ; 60 : 3559-67.
PubMed
39) Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings. Brain. 2020 ; 143 : 3104-20.
PubMed
40) Klein S, Davis F, Berman A, et al. A Case report of coronavirus disease 2019 presenting with tremors and gait disturbance. Clin Pract Cases Emerg Med. 2020 ; 4 : 324-6.
 
41) Kadali RAK, Janagama R, Yedlapati SH, et al. Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study. Am J Infect Control. 2022 ; 50 : 8-14.
PubMed
42) Gouse BM, Spears WE, Nieves Archibald A, et al. Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism. Brain Behav Immun. 2020 ; 89 : 529-30.
 
P.187 掲載の参考文献
1) Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 ; 77 : 683-90.
 
2) Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19 : The ALBA COVID registry. Neurology. 2020 ; 95 : e1060-70.
 
3) Moro E, Priori A, Beghi E. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur Neurol. 2020 ; 27 : 1727-37.
PubMed
4) Shimohata T. Neuro-COVID-19. Clin Exp Neuroimmunol. 2021.
PubMed
5) Garcia-Monco JC, Cabrera Muras A, Erburu Iriarte M, et al. Neurologic manifestations in a prospective unselected series of hospitalized patients with COVID-19. Neurol Clin Pract. 2021 ; 11 : e64-72.
 
6) Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020 ; 16 : 636-44.
PubMed
7) Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19 : A case report and systematic review. J Neurol. 2021 ; 268 : 3517-48.
PubMed
8) Salari M, Zaker Harofteh B, Etemadifar M, et al. Movement disorders associat ed with COVID-19. Parkinson Dis. 2021 ; 2021 : 3227753.
 
9) Brandao PRP, Grippe TC. New-onset movement disorders associated with COVID-19. Tremor Other Hyperkinet Mov (NY). 2021 ; 11 : 26.
 
10) Fadakar N, Ghaemmaghami S, Masoompour SM, et al. A first case of acute cerebellitis associated with coronavirus disease (COVID-19) : A case report and Literature Review.
PubMed
11) Werner J, Reichen I, Huber M, et al. Subacute cerebellar ataxia following respiratory symptoms of COVID-19 : A case report. BMC Infect Dis. 2021 ; 21 : 298.
 
12) Povlow A, Auerbach AJ. Acute cerebellar ataxia in COVID-19 infection : A case report. J Emerg Med. 2021 ; 60 : 73-6.
PubMed
13) Tomar LR, Shah DJ, Agarwal U, et al. Acute post-infectious cerebellar ataxia due to COVID-19. Mov Disord Clin Pract. 2021 ; 8 : 610-2.
PubMed
14) 小児COVID-19 関連多系統炎症性症候群 (MIS-C/PIMS) 診療コンセンサスステートメント [Internet]. 2021年9月16日.
 
15) Asan L, Klebe S, Kleinschnitz C, et al. Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19 : A case report. Ther Adv Neurol Disord. 2021 ; 14 : 17562864211062824.
 
16) Dijkstra F, Van den Bossche T, Willekens B, et al. Myoclonus and cerebellar ataxia following coronavirus disease 2019 (COVID-19). Mov Disord Clin Pract. 2020 ; 7 : 974-6.
 
17) Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ, et al. Reversible myoclonus-ataxia as a postinfectious manifestation of COVID-19. Mov Disord Clin Pract. 2020 ; 7 : 977-9.
PubMed
18) Shah PB, Desai SD. Opsoclonus myoclonus ataxia syndrome in the setting of COVID-19 infection. Neurology. 2021 ; 96 : 33.
PubMed
19) Foucard C, San-Galli A, Tarrano C, et al. Acute cerebellar ataxia and myoclonus with or without opsoclonus : a para-infectious syndrome associated with COVID-19. Eur Neurol. 2021 ; 28 : 3533-6.
PubMed
20) Chaumont H, San-Galli A, Martino F, et al. Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. J Neurol. 2020 ; 267 : 3121-7.
PubMed
21) Delorme C, Paccoud O, Kas A, et al. COVID-19-related encephalopathy : a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. 2020 ; 27 : 2651-7.
PubMed
22) Grimaldi S, Lagarde S, Harle JR, et al. Autoimmune encephalitis concomitant with SARS-CoV-2 infection : Insight from (18) F-FDG PET imaging and neuronal autoantibodies. J Nucl Med. 2020 ; 61 : 1726-9.
PubMed
23) Guerra AF, Martinelli I, Rispoli V, et al. Ataxia-myoclonus syndrome in patients with SARS-CoV-2 infection. Can J Neurol Sci. 2021 : 1-2.
PubMed
24) Wright D, Rowley R, Halks-Wellstead P, et al. Abnormal saccadic oscillations associated with severe acute respiratory syndrome coronavirus 2 encephalopathy and ataxia. Nov Disord Clin Pract. 2020 ; 7 : 980-2.
PubMed
25) Sanguinetti SY, Ramdhani RA. Opsoclonus-myoclonus-ataxia syndrome relat ed to the novel coronavirus (COVID-19). J Neuroophthalmol. 2021 ; 41 : e288-9.
 
26) O'Neill KA, Polavarapu A. Acute cerebellar ataxia associated with COVID-19 infection in a 5-year-old boy. Child Neurol Open. 2021 ; 8 : 2329048X211066755.
 
27) Balestrino R, Rizzone M, Zibetti M, et al. Onset of Covid-19 with impaired consciousness and ataxia : a case report. J Neurol. 2020 ; 267 : 2797-8.
PubMed
28) Hayashi M, Sahashi Y, Baba Y, et al. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci. 2020 ; 415 : 116941.
PubMed
29) Perrin P, Collongues N. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurd. 2021 ; 28 : 248-58.
PubMed
30) Malayala SV, Jaidev P, Vanaparthy R, et al. Acute COVID-19 cerebellitis : A rare neurological manifestation of COVID-19 infection. Cureus. 2021 ; 13 : e18505.
PubMed
31) Oosthuizen K, Steyn EC, Tucker L, et al. SARS-CoV-2 encephalitis presenting as a clinical cerebellar syndrome : A case report. Neurology. 2021 ; 97 : 27-9.
PubMed
32) Perrin P, Collongues N. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021 ; 28 : 248-58.
PubMed
33) Akcay N, Ogur M, Emin Menentoglu M, et al. Acute cerebellitis in MIS-C : A case report. Pediatr Infect Dis journal. 2021.
 
34) Landzberg DR, Bery E, Chico S, et al. Wernicke encephalopathy from olfactory dysfunction after COVID-19 infection. Neurologist. 2021 ; 26 : 274-5.
PubMed
35) Mirmosayyeb O, Bagherieh S, Shaygannejad V. Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine : A case report. Hum Vaccin Immunother. 2021 : 1-3.
 
36) Nishiguchi Y, Matsuyama H, Maeda K, et al. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. BMC Neurol. 2021 ; 21 : 452.
PubMed
P.194 掲載の参考文献
1) Debette S, de Seze J, Pruvo JP, et al. Long-term outcome of acute and subacute myelopathies. J Neurol. 2009 ; 256 : 980-8.
PubMed
2) Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020 ; 19 : 767-83.
 
3) Biyan NH, Hyeon JY. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021 ; 268 : 3059-71.
 
4) Rifino N, Censori B, Agazzi E, et al. Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol. 2021 : 268 : 2331-8.
 
5) Aguila-Gordo D, Flores-Barragan JM, Ferragut-Lloret F, et al. Acute myelitis and SARA-CoV2 infection. A new etiology of myelitis? J Clin Neurosci. 2020 ; 80 : 280-1. Published online 2020 Sep 30.
 
6) Mondal R, Deb S, Shome G, et al. COVID-19 and emerging spinal cord complications : A systematic review. Mult Scler Relat Disord. 2021 ; 51 : 102917. Published online 2021 Mar 21.
 
7) Roman GC, Gracia F, Torres A, et al. Acute transverse myelitis (ATM) : Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious advers events with the ChAdOx1 nCoV-19 vaccine (AZD 1222). Front Immunol. 2021 ; 12 : 653786. Published online 2021 Apr 26.
 
8) Barman A, Sahoo J, Viswanath A, et al. Clinical features, laboratory, and radiological findings of patients with acute inflammatory myelopathy after COVID-19 infection : A narrative review. Am J Phys Med Rehabil. 2021 ; 100 : 919-39. Published online 2021 Aug 4.
 
9) Guadarrama-Ortiz P, Choreno-Parra JA, Pacheco-Sanchez FJ, et al. Chronic subclinical spondylotic myelopathy exacerbated by COVID-19 : A case report. Interdiscip Neurosurg. 2021 ; 23 : 100896. Published online 2020 Sep 10.
 
10) 安藤哲朗, 林史恵, 福武敏夫. 脊髄炎の臨床的アプローチ. 脊椎脊髄 2021 ; 34 : 291-5.
 
11) Moore L, Ghannnam M, Manousakis G. A first presentation of multiple sclerosis with concurrent COVID-19 infection. eNeurologicalSci. 2021 : 100299. Epub 2020 Dec 4.
 
12) Palao M, Fernandez-Diaz E, Gracia-Gil J, et al. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord. 2020 ; 45 : 102377.
PubMed
13) da Costa MD, Rato ML, Cruz D, et al. Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection. J Neuroimmunol. 2021 ; 361 : 577739. Published online 2021 Oct 5.
 
14) Zhou S, Jones-Lopez EC, Soneji DJ, et al. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19. J Neuroophthalmol. 2020 ; 40 : 389-402. Published online 2020 Jun 26.
 
15) Jumah M, Rahman F, Figgie M, et al. COVID-19, HHV6, and MOG antibody : A perfect storm. J Neuroimmunol. 2021 ; 353 : 577521. Published online 2021 Feb 12.
 
16) Garg RK, Palwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022 ; 43 : 3-40.
 
17) Toljan K, Amin M, Kunchok A, et al. New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. J Neuroimmunol. 2022 ; 362 : 577785. Published online 2021 Dec 9.
 
18) Fujimori J, Miyazawa K, Nakashima I. Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNtech COVID-19 vaccine.J Neuroimmunol. 2021 ; 361 : 577755. Published online 2021 Oct 20.
 
P.200 掲載の参考文献
1) Koike H, Chiba A, Katsuno M. Emerging infection, vaccination, and Guillain-Barre syndrome : A review. Neurol Ther. 2021 ; 10 : 523-37.
PubMed
2) Zhao H, Shen D, Zhou H, et al. Guillain-Barre syndrome associated with SARS-CoV-2 infection : causality or coincidence? Lancet Neurol. 2020 ; 19 : 383-4.
PubMed
3) Gutierrez-Ortiz C, Mendez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020 ; 95 : e601-5.
PubMed
4) Decavel P, Nahmias O, Petit C, et al. Lower cranial nerve palsies in the COVID-19 pandemic : A 10-case series of intensive care unit patients. Eur Neurol. 2021 ; 23 : 1-4.
 
5) Castellani F, Cacciavillani M, Salvalaggio A, et al. Indirect effects of the lockdown for the COVID-19 pandemic : Comparative study of fibular palsies from prolonged sitting posture. eNeurologicalSci. 2021 ; 25 : 100385.
PubMed
6) Koike H, Katsuno, M. Macrophages and autoantibodies in demyelinating diseases. Cells. 2021 ; 10 : 844.
PubMed
7) Koike H, Katsuno, M. Emerging infectious diseases, vaccines, and Guillain-Barre syndrome. Clin Exp Neuroimmunol. 2021 May 17. in press.
 
8) Fragiel M, Miro O, Llorens P, et al. Incidence, clinical, risk factors and outcomes of Guillain-Barre in Covid-19. Ann Neurol. 2021 ; 89 : 598-603.
PubMed
9) Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain-Barre syndrome and COVID-19 : an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021 ; 92 : 751-6.
PubMed
10) Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. Brain. 2021 ; 144 : 682-93.
PubMed
11) Koike H, Katsuno, M. The role of macrophages in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. Neurol Clin Neurosci. 2021 ; 9 : 203-10.
 
12) Uncini A, Vallat JM, Jacobs BC. Guillain-Barre syndrome in SARS-CoV-2 infection : an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020 ; 91 : 1105-10.
PubMed
13) Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med. 2012 ; 366 : 2294-304.
PubMed
14) Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020 ; 382 : 2574-6.
PubMed
15) Chan M, Han SC, Kelly S, et al. A case series of Guillain-Barre syndrome after COVID-19 infection in New York. Neurol Clin Pract. 2021 ; 11 : e576-8.
 
16) Dufour C, Co TK, Liu A. GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome-A case report, systemic review and implication for vaccine development. Brain Behav Immun Health. 2021 ; 12 : 100203.
PubMed
17) Koike H, Fukami Y, Nishi R, et al. Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2020 ; 91 : 650-9.
PubMed
18) Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992 ; 31 : 677-9.
PubMed
19) Brugliera L, Filippi M, Del Carro U, et al. Nerve compression injuries after prolonged prone position ventilation in patients with SARS-CoV-2 : A case series. Arch Phys Med Rehabil. 2021 ; 102 : 359-62.
PubMed
20) Clarke KM, Riga V, Shirodkar AL, et al. Proning related bilateral anterior ischaemic optic neuropathy in a patient with COVID-19 related acute respiratory distress syndrome. BMC Ophthalmol. 2021 ; 21 : 276.
 
P.210 掲載の参考文献
1) Gilpin S, Byers M, Byrd A, et al. Rhabdomyolysis as the initial presentation of SARS-CoV-2 in an adolescent. Pediatrics. 2021 ; 147 : e2020019273.
 
2) Anwar H, Al Lawati A. Adolescent COVID-19-associated fatal rhabdomyolysis. J Prim Care Community Health. 2020 ; 11 : 1-3.
PubMed
3) Anklesaria Z, Frankman J, Gordin J, et al. Fatal rhabdomyolysis in a COVID-19 patient on rosuvastatin. Cureus. 2020 ; 12 : e11186.
 
4) Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy : a major cause of muscle weakness and paralysis. Lancet Neurol. 2011 ; 10 : 931-41.
 
5) Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve. 2005 ; 32 : 140-63.
PubMed
6) Madia F, Merico B, Primiano G, et al. Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Neurology. 2020 ; 95 : 492-4.
PubMed
7) Versace V, Sebastianelli L, Ferrazzoli D, et al. Case report : Myopathy in critically ill COVID-19 patients : A consequence of hyperinflammation? Front Neurol. 2021 ; 12 : 625144.
PubMed
8) Bax F, Lettieri C, Marini A, et al. Clinical and neurophysiological characterization of muscular weakness in severe COVID-19. Neurol Sci. 2021 ; 42 : 2173-8.
PubMed
9) Kayim Yildiz O, Yildiz B, et al. Clinical, neurophysiological and neuroimaging findings of critical illness myopathy after COVID-19. Cureus. 2021 ; 13 : e13807.
PubMed
10) Bagnato S, Boccagni C, Marino G, et al. Critical illness myopathy after COVID-19. Int J Infect Dis. 2020 ; 99 : 276-8.
PubMed
11) Tankisi H, Tankisi A, Harbo T, et al. Critical illness myopathy as a consequence of Covid-19 infection. Clin Neurophysiol. 2020 ; 131 : 1931-2.
PubMed
12) Frithiof R, Rostami E, Kumlien E, et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients : A prospective study. Clin Neurophysiol. 2021 ; 132 : 1733-40.
PubMed
13) Eslamian F, Taleschian-Tabrizi N, Izadseresht B, et al. Electrophysiologic findings in patients with COVID-19 and quadriparesia in the northwest of Iran, A case series study and literature review. Caspian J Intern Med. 2021 ; 12 (Suppl 2) : S451-9.
PubMed
14) Cabanes-Martinez L, Villadoniga M, Gonzalez-Rodriguez L, et al. Neuromuscular involvement in COVID-19 critically ill patients. Clin Neurophysiol. 2020 ; 131 : 2809-16.
PubMed
15) Zhang H, Charmchi Z, Seidman RJ, et al. COVID-19-associated myositis with severe proximal and bulbar weakness. Muscle Nerve. 2020 ; 62 : E57-60.
PubMed
16) Tanboon J, Nishino I. Classification of idiopathic inflammatory myopathies : pathology perspectives. Curr Opin Neurol. 2019 ; 32 : 704-14.
PubMed
17) Tanboon J, Uruha A, Stenzel W, et al. Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol. 2020 ; 33 : 590-603.
PubMed
18) Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020 ; 130 : 6409-16.
PubMed
19) Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression : A valuable marker of dermatomyositis. Neurology. 2017 ; 88 : 493-500.
 
20) Tanboon J, Nishino I. COVID-19-associated myositis may be dermatomyositis. Muscle Nerve. 2021 ; 63 : E9-10.
PubMed
21) Manzano GS, Woods JK, Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med. 2020 ; 383 : 2389-90.
PubMed
22) Sacchi MC, Tamiazzo S, Lauritano EC, et al. Case report of COVID-19 in an elderly patient : could SARS-CoV2 trigger myositis? Eur Rev Med Pharmacol Sci. 2020 ; 24 : 11960-3.
 
23) Shahidi Dadras M, Rakhshan A, Ahmadzadeh A, et al. Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection : A new potential trigger for musculoskeletal autoimmune disease development. Clin Case Rep. 2021 ; 9 : e04931.
PubMed
24) Gokhale Y, Patankar A, Holla U, et al. Dermatomyositis during COVID-19 pandemic (a case series) : Is there a cause effect relationship? J Assoc Physicians India. 2020 ; 68 : 20-4.
 
25) Lokineni S, Mortezavi M. Delayed-onset necrotizing myositis following COVID-19 infection. Eur J Case Rep Intern Med. 2021 ; 8 : 002461.
PubMed
26) Reggio C, Paudel A, Specht CS, et al. Necrotising myopathy and concurrent thyroiditis in a patient with COVID-19 infection. BMJ Case Rep. 2021 ; 14 : e242234.
 
27) Veyseh M, Koyoda S, Ayesha B. COVID-19 IgG-related autoimmune inflammatory necrotizing myositis. BMJ Case Rep. 2021 ; 14 : e239457.
PubMed
28) Mughal MS, Kaur IP, Alhashemi R, et al. Acute viral myositis complicated by rhabdomyolysis : a sole manifestation of COVID-19 infection. J Community Hosp Intern Med Perspect. 2021 ; 11 : 289-91.
PubMed
29) Almadani M, Shiferson A, Swearingen B, et al. Compartment syndrome secondary to viral myositis as initial presentation in COVID-19 patient. J Vasc Surg Cases Innov Tech. 2020 ; 6 : 524-7.
 
30) Hookey G, Ahmad Q, McCune T, et al. Diagnostic role of technitium-99m bone scan in severe COVID-19-associated myositis. Radiol Case Rep. 2021 ; 16 : 2123-8.
PubMed
31) Beydon M, Chevalier K, Al Tabaa O, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. 2020 ; 80 : e42.
PubMed
32) Uslu S. Myositis due to COVID-19. Postgrad Med J. 2021 ; 97 : 399.
PubMed
33) Mehan WA, Yoon BC, Lang M, et al. Paraspinal myositis in patients with COVID-19 infection. AJNR Am J Neuroradiol. 2020 ; 41 : 1949-52.
PubMed
34) Cassim F, Soni AJ, Murphy S. Severe acute inflammatory myositis and rhabdomyolysis in paediatric SARS-CoV-2-associated MIS-C (multisystem inflammatory syndrome in children). BMJ Case Rep. 2021 ; 14 : e243112.
PubMed
35) Islam B, Ahmed M, Islam Z, et al. Severe acute myopathy following SARS-CoV-2 infection : a case report and review of recent literature. Skelet Muscle. 2021 ; 11 : 10.
PubMed
36) Hooper JE, Uner M, Priemer DS, et al. Muscle biopsy findings in a case of SARS-CoV-2-associated muscle injury. J Neuropathol Exp Neurol. 2021 ; 80 : 377-8.
 
37) Suh J, Mukerji SS, Collens SI, et al. Skeletal muscle and peripheral nerve histopathology in COVID-19. Neurology. 2021 ; 97 : e849-58.
PubMed
38) Aschman T, Schneider J, Greuel S, et al. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol. 2021 ; 78 : 948-60.
PubMed
39) Capassoni M, Ketabchi S, Cassisa A, et al. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event : A case report. J Med Virol. 2021 ; 93 : 5718-20.
PubMed
40) Ramalingam S, Arora H, Lewis S, et al. COVID-19 vaccine-induced cellulitis and myositis. Cleve Clin J Med. 2021 ; 88 : 648-50.
PubMed
41) Theodorou DJ, Theodorou SJ, Axiotis A, et al. COVID-19 vaccine-related myositis. QJM. 2021 ; 114 : 424-5.
PubMed
42) Dodig D, Fritzler MJ, Naraghi A, et al. Immune-mediated necrotizing myopathy following BNT162b2 vaccination in a patient with antibodies against receptor-binding domain of SARS-CoV-2 and signal recognition particle. Muscle Nerve. 2021. Online ahead of print.
 
43) Maramattom BV, Philips G, Thomas J, et al. Inflammatory myositis after ChAdOx1 vaccination. Lancet Rheumatol. 2021 ; 3 : e747-9.
PubMed
44) Godoy IRB, Rodrigues TC, Skaf A. Myositis ossificans following COVID-19 vaccination. QJM. 2021 ; 114 : 659-60.
PubMed
45) Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2 : A case series. Eur J Neurol. 2022 ; 29 : 555-63.
PubMed
46) Blaise M, Rocher F, Spittler H, et al. Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma. J Eur Acad Dermatol Venereol. 2021 ; 36 : e100-2.
 
47) Tan A, Stepien KM, Narayana STK. Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis. QJM. 2021 ; 114 : 596-7.
PubMed
48) Hakroush S, Tampe B. Case report : ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizer-BioNTech COVID-19 mRNA vaccination. Front Immunol. 2021 ; 12 : 762006.
PubMed
49) Ajmera KM. Fatal case of rhabdomyolysis post-COVID-19 vaccine. Infect Drug Resist. 2021 ; 14 : 3929-35.
PubMed
50) Gelbenegger G, Cacioppo F, Firbas C, et al. Rhabdomyolysis Following Ad26. COV2.S COVID-19 Vaccination. Vaccines (Basel). 2021 ; 9 : 956.
PubMed
51) Elias C, Cardoso P, Goncalves D, et al. Rhabdomyolysis following administration of comirnaty ((R)). Eur J Case Rep Intern Med. 2021 ; 8 : 002796.
PubMed
52) Mack M, Nichols L, Guerrero DM. Rhabdomyolysis secondary to COVID-19 vaccination. Cureus. 2021 ; 13 : e15004.
PubMed
53) Kovvuru S, Nalleballe K, Onteddu SR, et al. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. J Neurol Sci. 2021 ; 420 : 117230.
PubMed
54) Peach E, Rutter M, Lanyon P, et al. Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic. Rheumatology (Oxford). 2021 ; 60 : 1902-9.
PubMed
55) Shinjo SK, de Souza FHC, Borges IBP, et al. Systemic autoimmune myopathies : A prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology (Oxford). 2021. Online ahead of print.
 
P.220 掲載の参考文献
1) Sagris D, Papanikolaou A, Kvernland A, et al. COVID-19 and ischemic stroke. Eur J Neurol. 2021 ; 28 : 3826-36.
PubMed
2) Daly SR, Nguyen AV, Zhang Y, et al. The relationship between COVID-19 infection and intracranial hemorrhage : A systematic review. Brain Hemorrhages. 2021 ; 2 : 141-50.
PubMed
3) Nawabi J, Morotti A, Wildgruber M, et al. Clinical and imaging characteristics in patients with SARS-CoV-2 infection and acute intracranial hemorrhage. J Clin Med. 2020 ; 9 : 2543.
 
4) Leasure AC, Khan YM, Lyer R, et al. Intracerebral hemorrhage in patients with COVID-19 : An analysis from the COVID-19 cardiovascular disease registry. Stroke. 2021 ; 52 : e321-3.
 
5) Kleineberg NN, Knauss S, Gulke E, et al. Neurological symptoms and complications in predominantly hospitalized COVID-19 patients : Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS). Eur J Neurol. 2021 ; 28 : 3925-37.
PubMed
6) Seeliger B, Dobler M, Friedrich R, et al. Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure. Crit Care. 2021 ; 24 : 701.
PubMed
7) Wang H, Tang X, Fan H, et al. Potential mechanisms of hemorrhagic stroke in elderly COVID-19 patients. Aging (Albany NY). 2020 ; 12 : 10022-34.
PubMed
8) Hernandez-Fernandez F, Valencia HS, Barbella-Aponte RA, et al. Cerebrovascular disease in patients with COVID-19 : neuroimaging, histological and clinical description. Brain. 2020 ; 143 : 3089-103.
 
9) Thakur KT, Miller EH, Glendinning MD, et al. COVID-19 neuropathology at Clolumbia University Irving Medical Center/New York Presbyterian hospital. Brain. 2021 ; 144 : 2696-708.
PubMed
10) Hokkoku K, Erra C, Cuccagna C, et al. Intensive care unit-acquired weakness and positioning-related peripheral nerve injuries in COVID-19 : A case series of three patients and the latest literature review. Brain Sci. 2021 ; 11 : 1177.
 
11) Hermans G, Van den Berghe G. Clinical review : Intensive care unit acquired weakness. Crit Care. 2015 ; 19 : 274.
 
12) McClafferty B, Umer I, Fye G, et al. Approach to critical illness myopathy and polyneuropathy in the older SARS-CoV-2 patients. J Clin Neurosci. 2020 ; 79 : 241-5.
PubMed
13) Kress JP, Hall JB. ICU-Acquired weakness and recovery from critical illness. N Engl J Med. 2014 ; 370 : 1626-35.
PubMed
14) Bax F, Lettieri C, Marini A, et al. Clinical and neurophysiological characterization of muscular weakness in severe COVID-19. Neuro Sci. 2021 ; 42 : 2173-8.
 
15) Frithiof R, Rostami E, Kumlien E, et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients. Clin Neurophysiol. 2021 ; 132 : 1733-40.
PubMed
16) Cabanes-Martinez L, Villadoniga M, Gonzalez-Rodriguez L, et al. Neuromuscular involvement in COVID-19 critically ill patients. Clin Neurophysiol. 2020 ; 131 : 2809-16.
PubMed
17) Van Aerde N, Van den Berghe G, Wilmer A, et al. Intensive care unit acquired muscle weakness in COVID-19 patients. Intensive Care Med. 2020 ; 46 : 2083-5.
PubMed
18) Weber-Carstens S, Maria D, Koch S, et al. Risk factors in critical illness myopathy during the early course of critical illness : a prospective observational study. Crit Care. 2010 ; 14 : R119.
 
19) Fernandez, CE, Franz CK, Ko JH, et al. Imaging review of peripheral nerve injuries in patients with COVID-19. Radiology 2021, 298, E117-30.
PubMed
20) Winfree CJ, Kline DG. Intraoperative positioning nerve injuries. Surg Neurol. 2005 ; 63 : 5-18.
PubMed
21) Malik GR, Wolfe AR, Soriano R, et al. Injury-prone : peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome. Br J Anaesth. 2020 ; 125 : e478-80.
PubMed
22) Bickler PE, Schapera A, Bainton CR. Acute radial nerve injury from use of an automatic blood pressure monitor. Anesthesiology. 1990 ; 73 : 186-8.
PubMed
23) Jang AY, Oh YJ, Lee SI, et al. Femoral neuropathy following venoarterial-extracorporeal membrane oxygenation. BMC Cardiovasc Disord. 2020 ; 20 : 393.
PubMed
24) Go JY, Min YS, Jung TD. Delayed onset of acute limb compartment syndrome with neuropathy after venoarterial extracorporeal membrane oxygenation therapy. Ann Rehabil Med. 2014 ; 38 : 575-80.
PubMed
25) Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, et al. Major neurologic adverse drug reactions, potential drug-drug Interactions and pharmacokinetic aspects of drugs used in COVID-19 patients with stroke : A narrative review. Ther Clin Risk Manag. 2020 ; 16 : 595-605.
PubMed
26) Bilbul M, Paparone P, Kim AM, et al. Psychopharmacology of COVID-19. Psychosomatics. 2020 ; 61 : 411-27.
PubMed
27) Borah P, Deb P K, Chandrasekaran B, et al. Consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients : Navigating the uncharted. Front Mol Biosci. 2021 ; 8 : 627723.
PubMed
28) ベクルリー点滴静注液100mg. https://www.mhlw.go.jp/content/10900000/230867_62504A3A1029_1_03_s.pdf 2021/12/17
 
29) Thomas ZR M, Leuppi-Taegtmeyer A, Jamiolkowski D, et al. Emerging treatments in COVID-19 : Adverse drug reactions including drug hypersensitivities. J Allergy Clin Immunol. 2020. 146 : 786-9.
 
30) Rezaee H, Pourkarim F, Pourtaghi-Anvarian S, et al. Drug-drug interactions with candidate medications used for COVID-19 treatment : An overview. Pharmacol Res Perspect. 2021 ; 9 : e00705.
PubMed
31) コミナティ筋注 副反応疑い報告の状況について. https://www.city.niiza.lg.jp/uploaded/attachment/44676.pdf 2021/12/17
 
32) Ekizoglu E, Gezegen H, Dikmen PY, et al. The characteristics of COVID-19 vaccine-related headache : Clues gathered from the healthcare personnel in the pandemic. Cephalalgia. 2022 ; 42 : 366-75.
 
33) Sekiguchi K, Watanabe N, Miyazaki N, et al. Incidence of headache after COVID-19 vaccination in patients with history of headache : A cross-sectional study. Cephalalgia. 2022 ; 42 : 266-72.
PubMed
34) Gobel CH, Heinze A, Karstedt S, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine : a multicentre observational cohort study. Brain Commun. 2021 ; 3 : fcab169.
PubMed
35) Mistry SG, Walker W, Earnshaw J, et al. COVID-19 swab-related skull base injury. Med J Aust. 2021 ; 214 : 457-9.e1.
 
36) Rajah J, Lee J. CSF rhinorrhoea post COVID-19 swab : A case report and review of literature. J Clin Neurosci. 2021 ; 86 : 6-9.
PubMed

IV パンデミック禍の神経診療の注意点と課題

P.233 掲載の参考文献
1) 永山正雄. COVID-19の主たる障害 : 神経障害の実態と対応. 日本医師会COVID-19有識者会議招待寄稿, 2021. https://www.covid19-jma-medical-expert-meeting.jp/topic/4041
 
2) Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19 : The ALBA COVID registry. Neurology. 2020 ; 95 : e1060-70.
 
3) Brigham and Women's Hospital, COVID-19 Protocols. https://covidprotocols.org/, 2020
 
4) Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology : Clinical, radiological and laboratory findings [published online ahead of print, 2020 Jul 8]. Brain. 2020 ; awaa240.
 
5) Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020 ; 19 : 767-83.
 
6) Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022.
PubMed
7) 一般財団法人日本救急医療財団. 救急蘇生法の指針 2020 医療従事者用. 東京 : へるす出版 ; 2022.
 
8) 一般社団法人日本蘇生協議会 (JRC). 病院における新型コロナウイルス感染症 (COVID-19) 対応救急蘇生法マニュアル. 2021. https://www.japanresuscitationcouncil.org/wp-content/uploads/2021/01/bac8ad9ef3599c413da93fd95e6c1d7d.pdf
 
9) 日本神経学会, 日本神経救急学会. 脳神経内科当直医のための, 新型コロナ感染を配慮した意識障害等の神経症候を呈する患者への救急外来対応マニュアル (ver 1). 2020. https://www.neurology-jp.org/covid/20200415_01.html
 
10) 一般社団法人日本蘇生協議会 (JRC). JRCからの勧告. https://www.japanresuscitationcouncil.org/ilcor国際コンセンサス-covid-19関係/
 
11) Nagayama M, Yang S, Geocadin RG, et al. Novel clinical features of nonconvulsive status epilepticus. F1000Res. 2017 ; 6 : 1690.
PubMed
12) Wartenberg K, Nagayama M, Neurocritical Care. In ; Venketasubramanian N, Anderson C, Ay H, et al. Stroke care during the COVID-19 pandemic : International expert panel review. Cerebrovasc Dis. 2021 ; 50 : 245-61.
 
13) Sutter R, Ruegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs : A systematic review. Neurology. 2015 ; 85 : 1332-41.
PubMed
14) Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012 ; 17 : 3-23.
PubMed
15) 黒田泰弘, 永山正雄, 監修. NeuroICUブック. 東京 : メディカルサイエンスインターナショナル 2021.
 
P.241 掲載の参考文献
1) Khosravani H, Rajendram P, Notario L, et al. Protected Code Stroke. Hyperacute stroke management during the coronavirus disease 2019 (COVID-19) pandemic. Stroke. 2020 ; 51 : 1891-5.
PubMed
2) 日本脳卒中学会 COVID-19対策プロジェクトチーム JSS-PCS作成ワーキンググループ. COVID-19対応脳卒中プロトコル (日本脳卒中学会版Protected Code Stroke : JSS-PCS). 脳卒中. 2020 ; 42 : 315-43.
 
3) 厚生労働省新型コロナウイルス感染症 (COVID-19) 診療の手引き・第6.0版. 令和2年度厚生労働行政推進事業費補助金 新興・再興感染症及び予防接種政策推進研究事業一類感染症等の患者発生時に備えた臨床的対応に関する研究. 2021年11月2日.
 
4) 日本放射線科専門医会・医会, 日本医学放射線学会, 日本環境感染学会, 日本感染症学会. 新型コロナウイルス感染症 (COVID-19) に対する胸部CT検査の指針 (Ver.1.0) 2020年4月23日. https://jcr.or.jp/covid19_2020/0423_ct_ver_1-0/
 
5) Baracchini C, Pieroni A, Viaro F, et al. Acute stroke management pathway during coronavirus-19 pandemic. Neurol Sci. 2020 ; 41 : 11-7.
 
6) 日本脳卒中学会脳卒中医療向上・社会保険委員会 静注血栓溶解療法指針改訂部会. 静注血栓溶解 (rt-PA) 療法適正治療指針 第三版 (2019年3月). 脳卒中. 2019 ; 41 : 205-46.
 
7) Faigle R, Butler J, Carhuapoma JR, et al. Safety trial of low-intensity monitoring after thrombolysis : Optimal Post Tpa-Iv Monitoring in Ischemic STroke (OPTIMIST). Neurohospitalist. 2020 ; 10 : 11-5.
PubMed
8) 日本脳卒中学会, 日本脳神経外科学会, 日本脳神経血管内治療学会. 経皮経管的脳血栓回収機器適正使用指針 第4版 2020年3月. 脳卒中. 2020 ; 42 : 281-313.
 
P.248 掲載の参考文献
1) Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021 ; 27 : 28-33.
PubMed
2) Roy J, Jain R, Golamari R, et al. COVID-19 in the geriatric population. Int J Greriatr Psychiatry. 2020 ; 35 : 1437-41.
 
3) Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia : Analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 ; 17 : 1297-306.
PubMed
4) Azarpazhooh MR, Amiri A, Morovatdar N, et al. Correlations between COVID-19 and burden of dementia : An ecological study and review of literature. J Neurol Sci. 2020 ; 416 : 117013.
PubMed
5) Sato K, Mano T, Niimi Y, et al. The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan : Evaluation of an administrative claims database. Biosci Trends. 2021 ; 15 : 219-30.
PubMed
6) Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care : 2020 report of the Lancet Commission. Lancet. 2020 ; 396 : 413-46.
PubMed
7) Maffioletti VLR, Baptista MAT, Santos RL, et al. Effectiveness of day care in supporting family caregivers of people with dementia : A systematic review. Dement Neuropsychol. 2019 ; 13 : 268-83.
PubMed
8) Sato K, Niimi Y, Iwatsubo T, et al. Change in the trend of long-term care service usage following COVID-19 pandemic in Japan : a survey using nationwide statistical summary in 2018-2021. medRxiv 2021121521267784. 2021.
 
9) Rainero I, Bruni AC, Marra C, et al. The impact of COVID-19 quarantine on patients with dementia and family caregivers : A nation-wide survey. Front Aging Neurosci. 2020 ; 12 : 625781.
PubMed
10) Cagnin A, Di Lorenzo R, Marra C, et al. Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia. Front Psychiatry. 2020 ; 11 : 578015.
PubMed
11) Suarez-Gonzalez A, Rajagopalan J, Livingston G, et al. The effect of COVID-19 isolation measures on the cognition and mental health of people living with dementia : A rapid systematic review of one year of quantitative evidence. EClinicalMedicine. 2021 ; 39 : 101047.
PubMed
12) Stifel SWF, Feinberg DK, Zhang Y, et al. Assessment during the COVID-19 pandemic : Ethical, legal, and safety considerations moving forward. School Psychology Review. 2020 ; 49 : 438-52.
 
13) Kitaigorodsky M, Loewenstein D, Curiel Cid R, et al. A teleneuropsychology protocol for the cognitive assessment of older adults during COVID-19. Front Psychol. 2021 ; 12 : 651136.
PubMed
14) Geddes MR, O'Connell ME, Fisk JD, et al. Remote cognitive and behavioral assessment : Report of the Alzheimer Society of Canada Task Force on dementia care best practices for COVID-19. Alzheimers Dement (Amst). 2020 ; 12 : e12111.
 
15) Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017 ; 177 : 1569-75.
 
16) Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline : 2021. Alzheimers Dement (N Y). 2021 ; 7 : e12179.
PubMed
17) Mackin RS, Insel PS, Truran D, et al. Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia : Results from the Brain Health Registry. Alzheimers Dement (Amst). 2018 ; 10 : 573-82.
 
18) Rentz DM, Papp KV, Mayblyum DV, et al. Association of digital clock drawing with PET amyloid and tau pathology in normal older adults. Neurology. 2021 ; 96 : e1844-e54.
PubMed
19) Tsoy E, Strom A, Iaccarino L, et al. Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery : sensitivity to Abeta and tau PET. Alzheimers Res Ther. 2021 ; 13 : 36.
PubMed
20) Lathan C, Spira JL, Bleiberg J, et al. Defense automated neurobehavioral assessment (DANA) -psychometric properties of a new field-deployable neuro cognitive assessment tool. Mil Med. 2013 ; 178 : 365-71.
 
21) www.cnsvs.com as of 12/17/2021
 
22) www.savonix.com as of 12/17/2021
 
23) verasci.com as of 12/17/2021
 
24) www.healthmeasures.net as of 12/17/2021
 
P.258 掲載の参考文献
1) 和田隆志. 厚生労働科学研究費補助金 難治性疾患政策研究事業 指定難病の普及・啓発に向けた統合研究 2018年度研究報告書.
 
2) 中山優季, 板垣ゆみ, 原口道子, 他. 難病患者の生活実態による新たな指定難病の類型化とその特徴～平成25年難病患者の生活実態全国調査から～. 日本難病看護学会誌. 2021 ; 26 : 173-84.
 
P.263 掲載の参考文献
1) Suh J, Amato AA. Neuromuscular complications of coronavirus disease-19. Curr Opin Neurol. 2021 ; 34 : 669-74.
PubMed
2) Businaro P, Vaghi G, Marchioni E, et al. COVID-19 in patients with myasthenia gravis : Epidemiology and disease course. Muscle Nerve. 2021 ; 64 : 206-11.
PubMed
3) Middleton RM, Craig EM, Rodgers WJ, et al. COVID-19 in multiple sclerosis : Clinically reported outcomes from the UK Multiple Sclerosis Register. Mult Scler Relat Disord. 2021 ; 56 : 103317.
PubMed
4) Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 severity in multiple sclerosis : Putting data into context. Neurol Neuroimmunol Neuroinflamm. 2021 ; 9 : e1105.
PubMed
5) Perez CA, Zhang GQ, Li X, et al. COVID-19 severity and outcome in multiple sclerosis : Results of a national, registry-based, matched cohort study. Mult Scler Relat Disord. 2021 ; 55 : 103217.
 
6) Garjani A, Middleton RM, Hunter R, et al. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord. 2021 ; 52 : 102939.
PubMed
7) Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple Sclerosis. Ann Neurol. 2021 ; 89 : 780-9.
PubMed
8) Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021 ; 97 : e1870-85.
PubMed
9) Louapre C, Ibrahim M, Maillart E, et al. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 ; 93 : 24-31.
 
10) Sormani MP, Schiavetti I, Landi D, et al. SARS-CoV-2 serology after COVID-19 in multiple sclerosis : An international cohort study. Mult Scler. 2021. in press.
 
11) Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021 ; 78 : 699-708.
 
12) https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/ms-treatment-guidelines-duringcoronavirus
 
13) Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis : What we have learnt by February 2021. Mult Scler. 2021 ; 27 : 864-70.
PubMed
14) Di Filippo M, Cordioli C, Malucchi S, et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022 ; 93 : 448-50.
 
15) https://www.neurology-jp.org/covid/pdf/20210827_01.pdf
 
16) Doneddu PE, Spina E, Briani C, et al. Acute and chronic inflammatory neuropathies and COVID-19 vaccines : Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP). J Peripher Nerv Syst. 2021 ; 26 : 148-54.
PubMed
17) Bsteh G, Durauer S, Assar H, et al. Humoral immune response after COVID-19 in multiple sclerosis : A nation-wide Austrian study. Mult Scler. 2021 ; 27 : 2209-18.
PubMed
18) Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021 ; 72 : 103581.
PubMed
19) Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021 ; 27 : 1990-2001.
PubMed
20) Tortorella C, Aiello A, Gasperini C, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. 2022 ; 98 : e541-e554.
 
21) Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I, et al. Guillain-Barre syndrome following COVID-19 vaccines : A scoping review. Acta Neurol Scand. 2022 ; 145 : 393-8.
PubMed
P.272 掲載の参考文献
1) Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019 : A review. JAMA Neurol. 2020 ; 77 : 1018-27.
PubMed
2) Voulgaris A, Ferini-Strambi L, Steiropoulos P. Sleep medicine and COVID-19. Has a new era begun? Sleep Med. 2020 ; 73 : 170-6.
 
3) Miller MA, Cappuccio FP. A systematic review of COVID-19 and obstructive sleep apnoea. Sleep Med Rev. 2021 ; 55 : 101382.
PubMed
4) Maas MB, Kim M, Malkani RG, et al. Obstructive sleep apnea and risk of COVID-19 infection, hospitalization and respiratory failure. Sleep Breath. 2021 ; 25 : 1155-7.
PubMed
5) Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res. 2021 ; 8 : e000845.
PubMed
6) Cade BE, Dashti HS, Hassan SM, et al. Sleep apnea and COVID-19 mortality and hospitalization. Am J Respir Crit Care Med. 2020 ; 202 : 1462-4.
PubMed
7) Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes : the CORONADO study. Diabetologia. 2020 ; 63 : 1500-15.
PubMed
8) Najafi A, Sadeghniiat-Haghighi K, Akbarpour S, et al. The effect of apnea management on novel coronavirus infection : A study on patients with obstructive sleep apnea. Sleep Health. 2021 ; 7 : 14-8.
 
9) Salles C, Mascarenhas Barbosa H. COVID-19 and obstructive sleep apnea. J Clin Sleep Med. 2020 ; 16 : 1647.
PubMed
10) Bhat S, Chokroverty S. Sleep disorders and COVID-19. Sleep Med. 2022 ; 91 : 253-61.
PubMed
11) Fowler RA, Guest CB, Lapinsky SE, et al. Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. Am J Respir Crit Care Med. 2004 ; 169 : 1198-202.
PubMed
12) World Health Organization. Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19). 2020 ; Interim guidance 19 March.
 
13) Barker J, Oyefeso O, Koeckerling D, et al. COVID-19 : community CPAP and NIV should be stopped unless medically necessary to support life. Thorax. 2020 ; 75 : 367.
PubMed
14) Miller R, Englund K. Transmission and risk factors of OF COVID-19. Cleve Clin J Med. 2020 May 14.
 
15) Tran K, Cimon K, Severn M, et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers : a systematic review. PLoS One. 2012 ; 7 : e35797.
PubMed
16) van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 ; 382 : 1564-7.
PubMed
17) Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J. 2019 ; 53 : 1802339.
PubMed
18) American Academy of Sleep Medicine (AASM). Coronavirus FAQs : CPAP tips for sleep apnea patients. 2020 ; March 17th. https://aasm.org/coronaviruscovid-19-faqs-cpap-sleep-apnea-patients/
 
19) Krishnan V. COVID-19 and home positive airway pressure (PAP) therapy. Am J Respir Crit Care Med. 2020 ; 201 : 28-9.
 
20) Thorpy M, Figuera-Losada M, Ahmed I, et al. Management of sleep apnea in New York city during the COVID-19 pandemic. Sleep Med. 2020 ; 74 : 86-90.
PubMed
21) Sole G, Salort-Campana E, Pereon Y, et al. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris) 2020 ; 176 : 507-15.
PubMed
22) Baker JG, Sovani M. Case for continuing community NIV and CPAP during the COVID-19 epidemic. Thorax. 2020 ; 75 : 368.
PubMed
23) England PH. COVID-19 : Guidance for infection prevention and control in healthcare settings. version 1.0.
 
24) Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020 ; 382 : 1177-9.
PubMed
25) 日本神経学会難病医療体制セクション. COVID-19に関連する筋ジストロフィー・重症心身障害児者・神経筋難病患者に対する呼吸ケアの注意点. 2020.
 
26) Schutte-Rodin S. Telehealth, telemedicine, and obstructive sleep apnea. Sleep Med Clin. 2020 ; 15 : 359-75.
PubMed
27) Spicuzza L, Sanna A. Continuum of care for patients with obstructive sleep apnea after one year from the COVID-19 pandemic onset : no time for further delays : Practical issues for a safe and effective management. Sleep Med. 2021 ; 84 : 98-106.
PubMed
28) Fujita H, Suzuki K. [NPPV treatment for neuromuscular diseases during the COVID-19 pandemic]. Brain Nerve. 2020 ; 72 : 1085-9.
PubMed
29) Karamouzos V, Fligou F, Gogos C, et al. High flow nasal cannula oxygen therapy in adults with COVID-19 respiratory failure. A case report. Monaldi Arch Chest Dis. 2020 ; 90 (2).
PubMed
30) Adir Y, Segol O, Kompaniets D, et al. COVID-19 : minimising risk to healthcare workers during aerosol-producing respiratory therapy using an innovative constant flow canopy. Eur Respir J. 2020 ; 55 : 2001017.
PubMed
31) Lucchini A, Giani M, Isgro S, et al. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation. Intensive Crit Care Nurs. 2020 ; 58 : 102859.
PubMed
32) Suen CM, Hui DSC, Memtsoudis SG, et al. Obstructive sleep apnea, obesity, and noninvasive ventilation : Considerations during the COVID-19 pandemic. Anesth Analg. 2020 ; 131 : 318-22.
PubMed
33) Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020 ; 92 : 552-5.
PubMed
34) Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth. 2020 ; 67 : 568-76.
PubMed
P.282 掲載の参考文献
1) 角田亘, 森井和枝, 後藤和也, 他. 新型コロナウイルス感染症 現場レポートCOVID-19 国際医療福祉大学成田病院リハビリテーションセンターからの現場レポート. 総合リハ. 2020 ; 48 : 866-7.
 
2) 園田茂. 不動・廃用症候群. Jpn J Rehabil Med. 2015 ; 52 : 265-71.
Medical*Online
3) 角田亘, 北原崇真. 嚥下障害に対する対応 嚥下障害のリハビリテーション. Clin Neurosci. 2019 ; 37 : 582-5.
 
4) 角田亘, 北原崇真. 認知リハビリテーション. In : 園生雅弘, 他編. 脳神経疾患最新の治療 2021-2023. 東京 : 南江堂 ; 2021. p.325-8.
 
5) 吉原一文. 心療内科で用いるストレス対処法 慢性疲労症候群の診療を通して. 難病と在宅ケア. 2019 ; 25 : 37-41.
Medical*Online
6) 江口真由美, 山口豊和, 上杉宗也. 通所リハビリテーションにおける異なる運動プログラムによる理学療法効果の検証. 理学療法学. 2009 ; 36 : 82-3.
Medical*Online
7) 山田実. 知っておくべきサルコペニアの予防と治療 運動によるサルコペニアの予防と治療. Medical Practice. 2020 ; 37 : 755-9.
 
8) 岡崎哲也. 高次脳機能障害者の就労支援を考える. Jpn J Rehabil Med. 2020 ; 57 : 329-33.
Medical*Online
9) 渡邉修. 就労/就学のためのリハビリテーション医療. In : 久保俊一, 他編. 脳血管障害のリハビリテーション医学・医療テキスト. 東京 : 医学書院 ; 2021. p.273-5.
 
10) 日本リハビリテーション医学会 リハビリテーション医療における安全管理・推進のためのガイドライン策定委員会, 編. 運動負荷を伴う訓練を実施するための基準. リハビリテーション医療における安全管理・推進のためのガイドライン 第2版. 東京 : 診断と治療社 ; 2019. p.23-58.
 
P.289 掲載の参考文献
1) Salerno M, Sessa F, Piscopo A, et al. No autopsies on COVID-19 deaths : a missed opportunity and the lockdown of science. J Clin Med. 2020 ; 9 : 1472.
 
2) Barth RF, Xu X, Buja LM. A call to action : the need for autopsies to determine the full extent of organ involvement associated with COVID-19. Chest. 2020 ; 158 : 43-4.
 
3) Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 ; 8 : 420-2.
 
4) World Health Organization. Infection prevention and control for the safe management of a dead body in the context of COVID-19 : internal guidance. Updated 24 March 2020. https://apps.who.int/iris/handle/10665/331538
 
5) Centers for Disease Control and Prevention (CDC). Collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19 (Interim guidance) 2020. Updated 2 Dec 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html
 
6) European Center for Disease Prevention and Control. Considerations related to the safe handling of bodies of deceased persons with suspected or confirmed COVID-19. Stockholm : ECDC ; 2020. Updated 23 March, 2020. https://www.ecdc.europa.eu/en/publications-data/considerations-related-safehandling-bodies-deceased-persons-suspected-or
 
7) College of American Pathologists. Amended COVID-19 autopsy guideline statement from the CAP autopsy committee. Updated Feb 2, 2021. https://documents.cap.org/documents/COVID-Autopsy-Statement.pdf
 
8) Caramaschi S, Kapp ME, Miller SE, et al. Histopathological findings and clinicopathologic correlation in COVID-19 : A systematic review. Mod Pathol. 2021 ; 34 : 1614-33.
PubMed
9) Maiese A, Manetti AC, Bosetti C, et al. SARS-CoV-2 and the brain : A review of the current knowledge on neuropathology in COVID-19. Brain Pathol. 2021 ; 31 : e13013.
 
10) Thakur K, Miller EH, Glendinning MD, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021 ; 144 : 2696-708.
PubMed
11) 吉田眞理. COVID-19の神経病理所見. In : 下畑享良, 編. COVID-19神経ハンドブック. 東京 : 中外医学社 ; 2022. p.70-7.
 
12) Adachi T, Chong J-M, Nakajima N, et al. Clinicopathologic and immunohistochemical findings from autopsy of patient with COVID-19, Japan. Emerg Inf Dis. 2020 ; 26 : 2157-61.
 
13) Okudela K, Hayashi H, Yoshimura Y, et al. A Japanese case of COVID-19 : an autopsy report. Pathol Int. 2020 ; 70 : 820-4.
PubMed
14) Takahashi K, Kajiura K, Nasu M, et al. Post-mortem biopsy of a patient with exacerbation of COVID-19 pneumonia. Respirol Case Rep. 2021 ; 9 : e00724.
PubMed
15) Amiya S, Hirata H, Shiroyama T, et al. Fatal cytomegalovirus pneumonia in a critically ill patient with COVID-19. Repirol Case Rep. 2021 ; 9 : e00801.
 
16) Tanomogi N, Otani T, Araki J, et al. Radiologically undetectable latent pulmonary lymphocyte infiltration suggesting the need for early glucocorticoid therapy : an autopsy case of rapidly progressive COVID-19 pneumonia with lymphopenia. Int Med. 2021 ; 60 : 2145-8.
 
17) Mizutani M, Nakayama Y, Saitoh Y, et al. Pathologic and neuropathologic study of a case of COVID-19. JMA J. 2022 ; 5 : 157-160.
PubMed
18) Takasu S, Ariizumi M, Matsumoto S, et al. Cerebral venous sinus thrombosis associated with COVID-19 : an autopsy case report. Forensic Sci Med Pathol. 2022 ; 18 : 80-5.
PubMed
19) 日本臨床衛生検査技師会. https://www.jamt.or.jp/会員専用ページ内 : COVID-19症例の剖検プロトコル 2020/2/25版. 新型コロナウイルス感染症 (COVID-19) の剖検における感染予防策 2020/02/19版.
 
20) 日本病理学会. 病理業務関連情報. https://pathology.or.jp/side/relatedinformation.html
 
21) 日本法医学会. http://www.jslm.jp/topics/20200302.html
 
22) 日本法医病理学会. http://houibyouri.kenkyuukai.jp/information/information_detail.asp?id=113856
 
23) 日本神経病理学会. http://prion.umin.jp/file/prion_autopsy_manual.pdf
 
24) 高尾昌樹. COVID-19における神経病理の重要性と課題. Brain Nerve. 2020 ; 72 : 1061-5.
 
P.297 掲載の参考文献
1) 西城卓也, 今福輪太郎, 恒川幸司, 他. Post COVID-19 時代の医療者教育における新たな再考テーマ : 医療者教育学修士課程の実践から. 医学教育. 2020 ; 51 : 351-3.
Medical*Online
2) Chen F, Lui AM, Martinelli SM. A systematic review of the effectiveness of flipped classrooms in medical education. Med Educ. 2017 ; 51 : 585-97.
PubMed
3) Russel J. A circumplex model of emotions. J Pers Soc Psychol. 1980 ; 39 : 1161-78.
 
4) Petrica A, Lungeanu D, Ciuta A, et al. Using 360-degree video for teaching emergency medicine during and beyond the COVID-19 pandemic. Ann Med. 2021 ; 53 : 1520-30.
PubMed
5) Parsons D, MacCallum K. Current perspectives on augmented reality in medical education : Applications, affordances and limitations. Adv Med Educ Pract. 2021 ; 12 : 77-91.
PubMed
6) ヴィゴツキー. 柴田義松, 訳. 思考と言語, 新訳版. 東京 : 新読書社 ; 2001.
 
7) Gormley GJ, Collins K, Boohan M. et al. Is there a place for e-learning in clinical skills? A survey of undergraduate medical students' experiences and attitudes. Med Teach. 2009 ; 31 (1) : e6-12.
 
8) Shikino K, Rosu CA, Yokokawa D, et al. Flexible e-learning video approach to improve fundus examination skills for medical students : a mixed-methods study. BMC Med Educ. 2021 ; 21 : 1-9.
PubMed
9) 西城卓也, 今福輪太郎. 脳神経内科領域における医学教育の展望 : Post/with コロナ時代を見据えて (Vol. 2) 現代の指導医に求められる「支援者的」臨床教育アプローチ. Brain Nerve. 2021 ; 73 : 1164-7.
 
P.305 掲載の参考文献
1) ICD-11 for Mortality and Morbidity Statistics (Version : 05/2021). https://icd.who.int/browse11/l-m/en. 2021年12月参照.
 
2) WHOホームページ. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid-19---11-march-2020 (掲載確認日 : 2022年1月10日).
 
2) Freudenberger H. Staff Burnout. J Soc Issues. 1974 ; 30 : 159-65.
 
3) Callard F, Perego E. How and why patients made Long COVID. Soc Sci Med. 2021 ; 268 : 113426.
PubMed
3) Maslach C, Jackson SE, Leiter MP. Maslach burnout inventory (3rd ed.). Palo Alto, CA : Consulting Psychologists Press ; 1996. p.1-52.
 
4) 久保真人. バーンアウトの心理学. 東京 : サイエンス社 ; 2004. p.1-215.
 
4) The BMJ Opinion. https://blogs.bmj.com/bmj/2020/10/01/why-we-need-tokeep-using-the-patient-made-term-long-covid/ (掲載確認日 : 2022年1月10日).
 
5) McCarthy J. Moral distress : Feeling compelled to do the wrong thing. 日本看護倫理学会誌. 2020 ; 12 : 4-10. (宮原香里他訳「道徳的苦悩 : 間違ったことをせざる得ない気持ち」)
 
5) The National Institute for Health and Care Excellence (NICE) guideline. 2021. https://www.nice.org.uk/guidance/ng188 (掲載確認日 : 2022年1月10日).
 
6) 米国疾病予防管理センター (CDC) ホームページ. Post-COVID Conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (掲載確認日 : 2022年1月10日).
 
6) Shanafelt TD, Boone S, Tan L, et al. Burnout and satisfaction with work-life balance among US physicians relative to the general US population. Arch Intern Med. 2012 ; 172 : 1377-85.
 
7) Williams ES, Konrad TR, Scheckler WE, et al. Understanding physicians' intentions to withdraw from practice : the role of job satisfaction, job stress, mental and physical health. Health Care Manage Rev. 2001 ; 26 : 7-19.
PubMed
7) 米国疾病予防管理センター (CDC) ホームページ. Evaluating and Caring for Patients with Post-COVID Conditions : Interim Guidance. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html (掲載確認日 : 2022年1月10日).
 
8) Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021 ; 594 : 259-64.
PubMed
8) West CP, Huschka MH, Novotny PJ, et al. Association of perceived medical errors with resident distress and empathy : a prospective longitudinal study. JAMA. 2006 ; 296 : 1071-8.
 
9) Panagioti M, Geraghty K, Johnson J, et al. Association between physician burnout and patient safety, professionalism, and patient satisfaction : a systematic review and meta-analysis. JAMA Intern Med. 2018 ; 178 : 1317-30.
PubMed
9) National Institute of the Health (NIH). NIH launches new initiative to study "Long COVID". https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid (掲載確認日 : 2022年1月10日).
 
10) 下畑享良, 久保真人, 饗場郁子, 他. 脳神経内科医におけるバーンアウトの現状と対策-第1報-. 臨床神経学. 2021 ; 61 : 89-102.
 
10) Nath A. Long-haul COVID. Neurology. 2020 ; 95 : 559-60.
PubMed
11) Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 ; 27 : 601-15.
PubMed
11) 久保真人, 饗場郁子, 下畑享良, 他. 脳神経内科医におけるバーンアウト (第2報) -男性医師と女性医師の比較-. 臨床神経学. 2021 ; 61 : 219-27.
 
12) DeChant PF, Acs A, Rhee KB, et al. Effect of organization-directed workplace interventions on physician burnout : A systematic review. Mayo Clin Proc Innov Qual Outcomes. 2019 ; 3 : 384-408.
PubMed
12) Halpin S, O'Connor R, Sivan M. Long COVID and chronic COVID syndromes. J Med Virol. 2021 ; 93 : 1242-3.
 
13) WHOホームページ. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (掲載確認日 : 2022年1月10日).
 
13) Busis NA, Shanafelt TD, Keran CM, et al. Burnout, career satisfaction, and well-being among US neurologists in 2016. Neurology. 2017 ; 88 : 797-808.
PubMed
14) Shanafelt TD, West CP, Sloan JA, et al. Career fit and burnout among academic faculty. Arch Intern Med. 2009 ; 169 : 990-5.
PubMed
14) 新型コロナウイルス感染症 (COVID-19) 診療の手引き 別冊罹患後症状のマネジメント (暫定版). 2021.
 
15) 久保真人. サービス業従事者における日本版バーンアウト尺度の因子的, 構成概念妥当性. 心理学研究. 2014 ; 85 : 364-72.
 
15) Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC) : An overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021 ; 12 : 698169.
PubMed
16) Ofei-Dodoo S, Loo-Gross C, Kellerman R. Burnout, depression, anxiety, and stress among family physicians in Kansas responding to the COVID-19 pandemic. JABFM. 2021 ; 34 : 522-30.
 
16) Sun J, Xiao J, Sun R, et al. Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg Infect Dis. 2020 ; 26 : 1834-8.
 
17) Faria ARQP, Coelho HFC, Silva AB, et al. Impact of the COVID-19 pandemic on the development of burnout syndrome in frontline physicians : prevalence and associated factors. Rev Assoc Med Bras. 2021 ; 67 : 942-9.
PubMed
17) Liotti FM, Menchinelli G, Marchetti S, et al. Assessment of SARS-CoV-2 RNA test results among patients who recovered from COVID-19 with prior negative results. JAMA Intern Med. 2021 ; 181 : 702-4.
PubMed
18) Omar DI, Hani BM, Abd-Ellatif EE. Burnout among Physicians in Egypt during COVID-19 Pandemic. The Egyptian Journal of Hospital Medicine. 2021 ; 82 : 599-608.
 
18) Chertow D, Stein S, Ramelli S, et al. SARS-CoV-2 infection and persistence throughoutthe human body and brain. (査読前論文). https://www.researchsquare.com/article/rs-1139035/v1 (掲載確認日 : 2022年1月10日).
 
19) Bangash MN, Owen A, Alderman JE, et al. COVID-19 recovery : potential treatments for post-intensive care syndrome. Lancet Respir Med. 2020 ; 8 : 1071-3.
PubMed
19) Wu Y, Wang J, Luo C, et al. Comparison of burnout frequency among oncology physicians and nurses working on the frontline and usual wards during the COVID-19 epidemic in Wuhan, China. J Pain Symptom Manag. 2020 ; 60 : e60-5.
 
20) 厚生労働科学特別研究事業 中間/最終報告. https://www.mhlw.go.jp/content/10900000/000798853.pdf (掲載確認日 : 2022年1月10日).
 
20) Dimitriu M, Pantea-Stoian A, Smaranda A, et al. Burnout syndrome in Romanian medical residents in time of the COVID-19 pandemic. Med Hypotheses. 2020 ; 144 : 109972.
PubMed
21) Office for National Statistics. https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications (掲載確認日 : 2020年1月10日).
 
21) Kodera S, Kimura Y, Tokairin Y, et al. Physician burnout in general hospitals turned into COVID-19 priority hospitals in Japan. JMA J. 2022 ; 5 : 118-23.
PubMed
22) 久保真人, 小寺志保, 井石秀明, 他 東京都COVID-19重点医療機関における医師の実態調査-自由記述の分析から. 日本医師会雑誌. 2022 ; 150 : 2021-5.
 
22) Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19 : A systematic review. JAMA Netw Open. 2021 ; 4 : e2111417.
 
23) Groff D, Sun A, Ssentongo AE, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection : A Systematic Review. JAMA Netw Open. 2021 ; 4 : e2128568.
PubMed
24) Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. 2021.
 
25) Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections#long-covid (掲載確認日 : 2020年1月10日).
 
26) Nakagawara K, Namkoong H, Terai H, et al. Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study : study protocol. BMJ Open Respir Res. 2021.
PubMed
27) 世田谷区ホームページ. 新型コロナウイルス感染症の後遺症についてのアンケート調査結果. https://www.city.setagaya.lg.jp/mokuji/fukushi/003/005/006/d00194382.html (掲載確認日 : 2022年1月10日).
 
28) Ishii M, Terai H, Kabata H, et al. Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan : A multicenter retrospective study. J Infect. 2020 ; 81 : e3-5.
PubMed
29) Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 ; 27 : 626-31.
PubMed
30) Phillips S, Williams M. Confronting our next national health disaster-long-haul Covid. N Engl J Med. 2021 ; 385 : 577-9.
PubMed
31) Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app : A prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021 ; 22 : 43-55.
 
32) Namkoong H, Edahiro R, Fukunaga K, et al. Japan COVID-19 Task Force : A nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan. medRxiv. 2020.
 
33) The COVID-19 host genetics initiative. https://www.covid19hg.org/ (掲載確認日 : 2022年1月10日).
 
34) 新興・再興感染症データバンク事業ナショナルレポジトリ (REBIND). https://rebind.ncgm.go.jp/ (掲載確認日 : 2022年1月10日)
 

V Long COVID と神経・精神症状

P.313 掲載の参考文献
1) WHOホームページ. COVID-19-China. https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229 (掲載確認日 : 2022年1月10日).
 
P.321 掲載の参考文献
1) A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021.
 
2) Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19 : A retrospective cohort study using electronic health records. Lancet Psychiatry. 2021 ; 8 : 416-27.
PubMed
3) Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features : A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021 ; 18 : e1003773.
PubMed
4) Beraki S, Aronsson F, Karlsson H, et al. Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice. Molecular psychiatry. 2005 ; 10 : 299-308.
PubMed
5) Mizutani M, Nakayama Y, Saitoh Y, et al. Pathologic and neuropathologic study of a case of COVID-19. pathologic and neuropathologic study of a case of COVID-19. JMA J. 2022 ; 5 : 157-60.
PubMed
6) 高尾昌樹. COVID-19における神経病理の重要性と課題 [Important and Unresolved Aspects of Neuropathologic Analyses of COVID-19 Individuals]. Brain and nerve = Shinkei kenkyu no shinpo. 2020 ; 72 : 1061-5.
 
7) 高尾昌樹, 水澤英洋, 中嶋秀人. 【Neuro-COVID-19】COVID-19の神経障害 わが国の現状 NCNPと日本神経学会による調査結果. Clin Neurosci. 2021 ; 39 : 319-22.
 
8) 高尾昌樹. 【Neuro-COVID-19】COVID-19の神経障害 髄膜脳炎・脳症. Clin Neurosci. 2021 ; 39 : 335-7.
 
9) 高尾昌樹. 【COVID-19がメンタルヘルスに与える影響】COVID-19による中枢神経系への影響. 臨床精神薬理. 2021 ; 24 : 989-94.
 
10) Becker JH, Lin JJ, Doernberg M, et al. Assessment of cognitive function in patients After COVID-19 infection. JAMA Network Open. 2021 ; 4 : e2130645.
PubMed
11) Valdes E, Fuchs B, Morrison C, et al. Demographic and social determinants of cognitive dysfunction following hospitalization for COVID-19. J Neurol Sci. 2022 : 120146.
PubMed
12) Shimohata T. Neuro-COVID-19. Clin EXP Neuroimmunol. 2021.
PubMed
13) Theoharides TC, Cholevas C, Polyzoidis K, et al. Long-COVID syndrome-associated brain fog and chemofog : Luteolin to the rescue. BioFactors (Oxford, England). 2021 ; 47 : 232-41.
 
14) Hugon J, Msika EF, Queneau M, et al. Long COVID : cognitive complaints (brain fog) and dysfunction of the cingulate cortex. J Neurol. 2022 ; 269 : 44-6.
PubMed
15) 佐藤和貴郎, 山村隆. 【COVID-19-その診断と治療】ブレインフォグ. カレントテラピー. 2021 ; 39 : 1046-51.
 
16) Naik S, Haldar SN, Soneja M, et al. Post COVID-19 sequelae : A prospective observational study from Northern India. Drug discov Ther. 2021 ; 15 : 254-60.
PubMed
17) 新型コロナウイルス感染症COVID-19診療の手引き 罹患後症状のマネジメント (暫定版) 2021. Available from : https://www.mhlw.go.jp>content.
 
P.326 掲載の参考文献
1) Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020 ; 371 : m4938.
PubMed
2) Nath A. Special editorial. Long-haul COVID. Neurology. 2020 ; 95 : 559-60.
 
3) Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med. 2021 ; 27 : 895-906.
PubMed
4) Tleyjeh IM, Saddik B, AISwaidan N, et al. Prevalence and predictors of post-acute COVID-19 syndrome (PACS) after hospital discharge : A cohort study with 4 months medican follow-up. PLoS One. 2021 ; 16 : e0260568.
 
5) 山村隆, 小野紘彦, 佐藤和貴郎. 筋痛性脳脊髄炎/慢性疲労症候群の免疫病態. 特集 筋痛性脳性髄炎/慢性疲労症候群の今. BRAIN and NERVE. 2018 ; 70 : 35-40.
 
6) Loebel M, Grabowski P, Heidecke H, et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016 ; 52 : 32-9.
PubMed
7) Fujii H, Sato W, Kimura Y, et al. Altered structural brain networks related to adrenergic/muscarinic receptor autoantibodies in chronic fatigue syndrome. J Neuroimaging 2020 ; 30 : 822-7.
PubMed
8) Sato W, Ono H, Matsutani T, et al. Skewing of the B cell receptor repertoire in myaligic encephalomyelitis/chronic fatigue syndrome. Brain Behav Immun. 2021 ; 95 : 245-55.
 
9) Sotzny F, Blanco J, Capelli E, et al. Myalgic encephalomyelitis/chronic fatigue syndrome-Evidence for an autoimmune disease. Autoimmun Rev. 2018 ; 17 : 601-9.
PubMed
10) Wirth K, Scheibenbogen C. A unifying hypothesis of the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) : Recognitions of the findings of autoantibodies against β2-adrenergic receptors. Autoimmun Rev. 2020 : 19 : 102527.
 
11) Apple AC, Oddi A, Peluso MJ, et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Trans Neurol. 2022 ; 9 : 221-6.
 
12) Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19 : potential mechanisms of disease. Brain. 2021 ; 144 : 3576-88.
PubMed
P.334 掲載の参考文献
1) Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul : Autonomic complications of COVID-19. Auton Neurosci. 2021 ; 235 : 102841.
 
2) Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection : a case series of 20 patients. Immunol Res. 2021 ; 69 : 205-11.
PubMed
3) Shouman K, Vanichkachorn G, Cheshire WP, et al. Autonomic dysfunction following COVID-19 infection : An early experience. Clin Auton Res. 2021 ; 31 : 385-94.
PubMed
4) Agarwal AK, Garg R, Ritch A, et al. Postural orthostatic tachycardia syndrome. Postgrad Med J. 2007 ; 83 : 478-80.
PubMed
5) Miglis MG, Prieto T, Shaik R, et al. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020 ; 30 : 449-51.
 
6) Bisaccia G, Ricci F, Recce V, et al. Post-acute sequelae of COVID-19 and cardiovascular autonomic dysfunction : What do we know? J Cardiovasc Dev Dis. 2021 ; 8 : 156.
 
7) Kanjwal K, Jamal S, Kichloo A, et al. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. J Innov Card Rhythm Manag. 2020 ; 11 : 4302-4.
PubMed
8) Rass V, Beer R, Schiefecker AJ, et al. Neurological outcome and quality of life 3 months after COVID-19 : A prospective observational cohort study. Euro J Neuro. 2021 ; 28 : 3348-59.
 
9) Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome : The Mayo clinic experience. Mayo Clin Proc. 2007 ; 82 : 308-13.
 
10) Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome-insights from a large cross-sectional online community-based survey. J Intern Med. 2019 ; 286 : 438-48.
PubMed
11) Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID' : Rationale, physiology and management strategies. Clin Med (Lond). 2021 ; 21 : e63-7.
 
12) Johansson M, Stahlberg M, Runold M, et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome : The Swedish experience. JACC Case Rep. 2021 ; 3 : 573-80.
PubMed
13) Vernino S, Stiles LE. Autoimmunity in postural orthostatic tachycardia syndrome : Current understanding. Auton Neurosci. 2018 ; 215 : 78-82.
PubMed
14) Fedorowski A. Postural orthostatic tachycardia syndrome : clinical presentation, aetiology and management. J Intern Med. 2019 ; 285 : 352-66.
PubMed
15) Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021 ; 4 : 100100.
PubMed
16) Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity. 2005 ; 38 : 235-45.
PubMed
17) Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol. 2013 ; 61 : 793-801.
PubMed
18) Desai AD, Boursiquot BC, Moore CJ, et al. Autonomic dysfunction post-acute COVID-19 infection. HeartRhythm Case Rep. 2022 ; 8 : 143-6.
PubMed
19) Novak P. Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy : a case report. eNeurologicalSci. 2020 ; 21 : 100276.
PubMed
20) Barizien N, Le Guen M, Russel S, et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021 ; 11 : 14042.
PubMed
21) Sletten DM, Suarez GA, Low PA, et al. COMPASS 31 : A refined and abbreviated composite autonomic symptom score. Mayo Clin Proc. 2012 ; 87 : 1196-201.
PubMed
22) Buoite Stella A, Furlanis G, Frezza NA, et al. Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms : A prospective multidomain observational study. J Neurol. 2022 ; 269 : 587-96.
PubMed
23) Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome : An American Autonomic Society statement. Clin Auton Res. 2021 ; 31 : 365-8.
PubMed
P.342 掲載の参考文献
1) Cascella M, Del Gaudio A, Vittori A, et al. COVID-pain : Acute and late-onset painful clinical manifestations in COVID-19-molecular mechanisms and research perspectives. J Pain Res. 2021 ; 14 : 2403-12.
PubMed
2) Costa AC, Romero TR, Pacheco DF, et al. Participation of AT1 and Mas receptors in the modulation of inflammatory pain. Peptides. 2014 ; 61 : 17-22.
PubMed
3) Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science. 2016 ; 354 : 572-7.
PubMed
4) Meyer-Friessem CH, Gierthmuhlen J, Baron R, et al. Pain during and after COVID-19 in Germany and worldwide : A narrative review of current knowledge. Pain Rep. 2021 ; 6 : e893.
PubMed
5) Caronna E, Pozo-Rosich P. Headache as a symptom of COVID-19 : Narrative review of 1-year research. Curr Pain Headache Rep. 2021 ; 25 : 73.
PubMed
6) Garcia-Azorin D, Sierra A, Trigo J, et al. Frequency and phenotype of headache in covid-19 : a study of 2194 patients. Sci Rep. 2021 ; 11 : 14674.
 
7) Dos Anjos de Paula RC, de Maria Frota Vasconcelos T, da Costa FBS, et al. Characterization of headache in COVID-19 : A retrospective multicenter study. Mol Neurobiol. 2021 ; 58 : 4487-94.
PubMed
8) Sampaio Rocha-Filho PA, Albuquerque PM, Carvalho L, et al. Headache, anosmia, ageusia and other neurological symptoms in COVID-19 : A cross-sectional study. J Headache Pain. 2022 ; 23 : 2.
PubMed
9) Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021 ; 24 : 168-75.
PubMed
10) Nwajei F, Anand P, Abdalkader M, et al. Cerebral venous sinus thromboses in patients with SARS-CoV-2 infection : Three cases and a review of the literature. J Stroke Cerebrovasc Dis. 2020 ; 29 : 105412.
 
11) Arandela K, Samudrala S, Abdalkader M, et al. Reversible cerebral vasoconstriction syndrome in patients with coronavirus disease : A multicenter case series. J Stroke Cerebrovasc Dis. 2021 ; 30 : 106118.
 
12) Motolese F, Ferrante M, Rossi M, et al. Posterior reversible encephalopathy syndrome and brain haemorrhage as COVID-19 complication : A review of the available literature. J Neurol. 2021 ; 268 : 4407-14.
PubMed
13) Fernandez-de-Las-Penas C, Navarro-Santana M, Gomez-Mayordomo V, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors : A meta-analysis of the current literature. Eur J Neurol. 2021 ; 28 : 3820-5.
PubMed
14) Otsuka Y, Tokumasu K, Nakano Y, et al. Clinical characteristics of Japanese patients who visited a COVID-19 aftercare clinic for post-acute sequelae of COVID-19/long COVID. Cureus. 2021 ; 13 : e18568.
PubMed
15) Fernandez-de-Las-Penas C, Gomez-Mayordomo V, Cuadrado ML, et al. The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue : A case-control study. Cephalalgia. 2021 ; 41 : 1332-41.
PubMed
16) Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020 ; 15 : 646-55.
 
17) Sekiguchi K, Watanabe N, Miyazaki N, et al. Incidence of headache after COVID-19 vaccination in patients with history of headache : A cross-sectional study. Cephalalgia. 2021 : 3331024211038654.
PubMed
18) Gobel CH, Heinze A, Karstedt S, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine : a multicentre observational cohort study. Brain Commun. 2021 ; 3 : fcab169.
PubMed
19) Gobel CH, Heinze A, Karstedt S, et al. Headache attributed to vaccination against COVID-19 (coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine : A multicenter observational cohort study. Pain Ther. 2021 ; 10 : 1309-30.
PubMed
20) Ekizoglu E, Gezegen H, Yalinay Dikmen P, et al. The characteristics of COVID-19 vaccine-related headache : Clues gathered from the healthcare personnel in the pandemic. Cephalalgia. 2021 : 3331024211042390.
PubMed
21) Silvestro M, Tessitore A, Orologio I, et al. Headache worsening after COVID-19 vaccination : An online questionnaire-based study on 841 patients with migraine. J Clin Med. 2021 ; 10 : 5914.
 
22) Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022 ; 43 : 3-40.
PubMed
23) Chuang TY, Burda K, Teklemariam E, et al. Tolosa-Hunt syndrome presenting after COVID-19 vaccination. Cureus. 2021 ; 13 : e16791.
PubMed
P.348 掲載の参考文献
1) Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome : A meta-analysis. J Neurol Sci. 2022 ; 434 : 120162.
 
2) Carenzo L, Protti A, Dalla Corte F, et al. Short-term health-related quality of life, physical function and psychological consequences of severe COVID-19. Ann Intensive Care. 2021 ; 11 : 91.
PubMed
3) Writing Committee for the CSG, Morin L, Savale L, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021 ; 325 : 1525-34.
 
4) Schandl A, Hedman A, Lynga P, et al. Long-term consequences in critically ill COVID-19 patients : A prospective cohort study. Acta Anaesthesiol Scand. 2021 ; 65 : 1285-92.
PubMed
5) Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA. 2022 ; 327 : 559-65.
PubMed
6) Geense WW, Zegers M, Peters MAA, et al. New physical, mental, and cognitive problems 1 year after ICU admission : A prospective multicenter study. Am J Respir Crit Care Med. 2021 ; 203 : 1512-21.
PubMed
7) Theoharides TC, Cholevas C, Polyzoidis K, et al. Long-COVID syndrome-associated brain fog and chemofog : Luteolin to the rescue. Biofactors. 2021 ; 47 : 232-41.
 
8) Najjar S, Najjar A, Chong DJ, et al. Central nervous system complications associated with SARS-CoV-2 infection : Integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020 ; 17 : 231.
PubMed
9) Morin CM, Bjorvatn B, Chung F, et al. Insomnia, anxiety, and depression during the COVID-19 pandemic : an international collaborative study. Sleep Med. 2021 ; 87 : 38-45.
PubMed
10) Schweitzer F, Kleineberg NN, Goreci Y, et al. Neuro-COVID-19 is more than anosmia : Clinical presentation, neurodiagnostics, therapies, and prognosis. Curr Opin Neurol. 2021 ; 34 : 423-31.
PubMed
11) Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany : A post-mortem case series. Lancet Neurol. 2020 ; 19 : 919-29.
 
12) Poloni TE, Medici V, Moretti M, et al. COVID-19-related neuropathology and microglial activation in elderly with and without dementia. Brain Pathol. 2021 ; 31 : e12997.
PubMed
13) Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19) : A review. Int J Surg. 2020 ; 78 : 185-93.
PubMed
14) Gunnell D, Appleby L, Arensman E, et al. Suicide risk and prevention during the COVID-19 pandemic. Lancet Psychiatry. 2020 ; 7 : 468-71.
PubMed
15) Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020 ; 87 : 100-6.
PubMed
16) Pirkis J, John A, Shin S, et al. Suicide trends in the early months of the COVID-19 pandemic : An interrupted time-series analysis of preliminary data from 21 countries. Lancet Psychiatry. 2021 ; 8 : 579-88.
PubMed
17) Sakamoto H, Ishikane M, Ghaznavi C, et al. Assessment of suicide in Japan during the COVID-19 pandemic vs previous years. JAMA Netw Open. 2021 ; 4 : e2037378.
PubMed
18) Horita N, Moriguchi S. Trends in suicide in Japan following the 2019 coronavirus pandemic. JAMA Netw Open. 2022 ; 5 : e224739.
PubMed
19) Wickens CM, McDonald AJ, Elton-Marshall T, et al. Loneliness in the COVID-19 pandemic : Associations with age, gender and their interaction. J Psychiatr Res. 2021 ; 136 : 103-8.
PubMed
20) Kourti A, Stavridou A, Panagouli E, et al. Domestic violence during the COVID-19 pandemic : A systematic review. Trauma Violence Abuse. 2021 : 15248380211038690.
PubMed
P.355 掲載の参考文献
1) Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild to moderate forms of the coronavirus disease (COVID-19) : A multicenter european study. Eur Arch Otorhinolaryngol. 2020 ; 277 : 2251-61.
PubMed
2) Hopkins C, Surda P, Whitehead E, et al. Early recovery following new onset anosmia during the COVID-19 pandemic-an observational cohort study. J Otolaryngol Head Neck Surg. 2020 ; 49 : 26.
PubMed
3) Eliezer M, Hamel AL, Houdart E, et al. Loss of smell in patients with COVID-19 : MRI data reveal a transient edema of the olfactory clefts. Neurology. 2020 ; 95 : e3145-52.
 
4) Ueha R, Kondo K, Kagoya R, et al. ACE2, TMPRSS2, and furin expression in the nose and olfactory bulb in mice and humans. Rhinology. 2021 ; 59 : 105-9.
PubMed
5) Khan M, Yoo SJ, Clijsters, et al. Visualizing in decreased COVID-10 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021 ; 184 : 5932-49.
 
6) Bryche B, St Albin A, Murri S, et al. Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav Immun. 2020 ; 579-86.
PubMed
7) Bilinska K, Butowt R. Anosmia in COVID-19 : A bumpy road to establishing a cellular mechanism. ACS Chem Neurosci. 2020 ; 11 : 2152-5.
PubMed
8) 厚生労働科学研究成果データベース. 新型コロナウイルス感染症による嗅覚, 味覚障害の機序と疫学, 予後の解明に資する研究. https://mhlw-grants.niph.go.jp/project/146094 (2022/02/14)
 
9) Tong JY, Wong A, Zhu D Ll, et sl. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients : A systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020 ; 163 : 3-11.
 
10) SARS-CoV-2 variants of concern and variants under investication in England. Technical briefing 34. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050236/technical-briefing-34-14-january-2022.pdf (2022/02/14)
 
11) Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 omicron variant in Norway, november to december 2021. Euro Surveill. 2021 ; 26 : 2101147.
PubMed
12) 新型コロナウイルス感染症 診療の手引き 別冊罹患後症状のマネジメント. https://ajhc.or.jp/siryo/covid-betu.pdf (2022/02/14)
 
13) Hummel T, Rissom K, Reden J, et al. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009 ; 119 : 496-9.
PubMed
14) 日本鼻科学会嗅覚障害診療ガイドライン作成委員会. 嗅覚障害診療ガイドライン. 日鼻誌. 2017 ; 56 : 487-556.
 
15) Ogawa T, Nakamura K, Yamamoto S, et al. Recovery over time and prognostic factors in treated patients with post-infectious olfactory dysfunction : A retrospective study. Ann Otol Rhinol Laryngol. 2020 ; 129 : 977-82.
PubMed
P.363 掲載の参考文献
1) Chou SH-Y, Beghi E, Helbok R, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19-A report for the GCS-neuroCOVID consortium and the ENERGY consortium. JAMA Netw Open. 2021 ; 4 : e2112131.
 
2) Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020 ; 324 : 603-5.
 
3) Couzin-Frankel J. The long haul. Science. 2020 ; 369 : 614-7.
 
4) Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 ; 27 : 601-15.
PubMed
5) Mahase E. COVID-19 : What do we know about "long covid"? BMJ. 2020 ; 370 : m2815.
PubMed
6) Callard F. Epidemic time : Thinking from the Sickbed. Bull Hist Med. 2020 ; 94 : 727-43.
PubMed
7) Anaya J-M, Rojas M, Salinas ML, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021 ; 20 : 102947.
PubMed
8) Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people [Internet]. medRxiv. 2021. Available from : http://medrxiv.org/lookup/doi/10.1101/2021.06.28.21259452
 
9) Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 ; 27 : 626-31.
PubMed
10) Blomberg B, Mohn KG-I, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021 ; 27 : 1607-13.
 
11) Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 "long haulers." Ann Clin Transl Neurol. 2021 ; 8 : 1073-85.
PubMed
12) Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19 : a retrospective cohort study using electronic health records. The Lancet Psychiatry. 2021 ; 8 : 416-27.
PubMed
13) Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features : A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021 ; 18 : e1003773.
PubMed
14) Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital : a cohort study. Lancet. 2021 ; 397 : 220-32.
 
15) Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections : a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020 ; 7 : 611-27.
 
16) Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul : Autonomic complications of COVID-19. Auton Neurosci. 2021 ; 235 : 102841.
 
17) Xydakis MS, Albers MW, Holbrook EH, et al. Post-viral effects of COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021 ; 20 : 753-61.
PubMed
18) Ohla K, Veldhuizen MG, Green T, et al. Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss [Internet]. bioRxiv. 2021. Available from : http://medrxiv.org/lookup/doi/10.1101/2021.08.28.21262763
 
19) Rogers-Brown JS, Wanga V, Okoro C, et al. Outcomes Among Patients Referred to Outpatient Rehabilitation Clinics After COVID-19 diagnosis-United States, January 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 967-71.
PubMed
20) Pandharipande PP, Girard TD, Ely EW. Long-term cognitive impairment after critical illness. N Engl J Med. 2014 ; 370 : 185-6.
PubMed
21) Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021 ; 595 : 565-71.
PubMed
22) Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021 ; 595 : 283-8.
PubMed
23) Schweitzer F, Goereci Y, Franke C, et al. Cerebrospinal fluid analysis post-COVID-19 is not suggestive of persistent central nervous system infection. Ann Neurol. 2022 ; 91 : 150-7.
 
24) Guedj E, Campion JY, Dudouet P, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021 ; 48 : 2823-33.
PubMed
25) Blazhenets G, Schroeter N, Bormann T, et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. 2021 ; 62 : 910-5.
 
26) Beghi E, Giussani G, Westenberg E, et al. Acute and post-acute neurological manifestations of COVID-19 : present findings, critical appraisal, and future directions. J Neurol [Internet]. 2021 ; Available from : http://dx.doi.org/10.1007/s00415-021-10848-4
 
27) Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel : a cross-sectional study of patients tested between March 2020 and November 2021 [Internet]. bioRxiv. 2022. Available from : http://medrxiv.org/lookup/doi/10.1101/2022.01.05.22268800
 
28) Sipila PN, Heikkila N, Lindbohm JV, et al. Hospital-treated infectious diseases and the risk of dementia : a large, multicohort, observational study with a replication cohort. Lancet Infect Dis. 2021 ; 21 : 1557-67.
PubMed

VI ワクチンと副反応

P.375 掲載の参考文献
1) 一般社団法人日本感染症学会 ワクチン委員会・COVID-19ワクチン・タスクフォース. COVID-19ワクチンに関する提言 (第4版). p3. https://www.kansensho.or.jp/uploads/files/guidelines/2112_covid-19_4kasen.pdf
 
2) Versteeg L, Almutairi MM, Hotez PJ, et al. Enlisting the mRNA vaccine platform to combat parasitic infections. Vaccines (Basel). 2019 ; 7 : 122.
 
3) Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak situations. Front Immunol. 2018 ; 9 : 1963.
PubMed
4) 日本神経学会. COVID-19ワクチンに関する日本神経学会の見解. https://www.neurology-jp.org/covid/index.html
 
5) Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 ; 383 : 2603-15.
PubMed
6) Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 ; 384 : 403-16.
PubMed
7) Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 ; 397 : 99-111.
PubMed
8) Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 ; 385 : 39-50.
 
9) Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021 ; 385 : 2241-51.
PubMed
10) Centers for Disease Control and Prevention. CDC Real-World Study Confirms Protective Benefits of mRNA COVID-19 Vaccines. https://www.cdc.gov/media/releases/2021/p0329-COVID-19-Vaccines.html
 
11) Centers for Disease Control and Prevention. Fully Vaccinated Adults 65 and Older Are 94% Less Likely to Be Hospitalized with COVID-19. https://www.cdc.gov/media/releases/2021/p0428-vaccinated-adults-less-hospitalized.html
 
12) Centers for Disease Control and Prevention. Largest CDC COVID-19 Vaccine Effectiveness Study in Health Workers Shows mRNA Vaccines 94% Effective. https://www.cdc.gov/media/releases/2021/p0514-covid-19-vaccineeffectiveness.html
 
13) Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021 ; 384 : 1412-23.
 
14) El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021 ; 385 : 1774-85.
 
15) 国立感染症研究所感染症疫学センター. 新型コロナワクチンの有効性を検討した症例対照研究の暫定報告 (第一報). https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10614-covid19-55.html
 
16) Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021 ; 326 : 2043-54.
PubMed
17) Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021 ; 372 : eabg3055.
PubMed
18) Muik A, Wallisch AK, Sanger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021 ; 371 : 1152-3.
PubMed
19) Wu K, Werner AP, Moliva JI, et al. mRNA-273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021 Jan 25 ; 2021.01.25.427948. doi : 10.1101/2021.01.25.427948.
 
20) Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021 ; 397 : 2331-3.
 
21) Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 ; 596 : 273-5.
 
22) Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021 ; 385 : 585-94.
 
23) Skowronski DM, Setayeshgar S, Febriani Y, et al. Two dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals : test negative design studies from British Columbia and Quebec, Canada. medRxiv. 2021. doi : https://doi.org/10.1101/2021.10.26.21265397
 
24) 国立感染症研究所感染症疫学センター. 新型コロナワクチンの有効性を検討した症例対 照研究の暫定報告 (第二報). https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10757-covid19-61.html
 
25) Genomic epidemiology of novel coronavirus-Global subsampling. https://nextstrain.org/ncov/gisaid/global
 
26) Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa 2021-12-01. medRxiv. 2021.
 
27) Pfizer. Pfizer and BioNTech provide update on Omicron variant. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechprovide-update-omicron-variant
 
28) Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 Months. N Engl J Med. 2021 ; 385 : e84.
PubMed
29) Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021 ; 385 : 2413-20.
PubMed
30) Spitzer A, Angel Y, Marudi O, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA. 2022 Jan 10. doi : 10.1001/jama.2021.23641. Online ahead of print.
 
31) Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021 ; 385 : 2421-30.
PubMed
32) Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. https://khub.net/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+Omicron+variant+of+concern.pdf/f423c9f4-91cb-0274-c8c5-70e8fad50074
 
33) コミナティ筋注 添付文書. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/672212_631341DA1025_1_10
 
34) スパイクバックス筋注 添付文書. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400256_631341EA1038_1_02
 
35) バキスゼブリア筋注 適正使用ガイド. https://www.town.inagawa.lg.jp/ikkrwebBrowse/material/files/group/42/cc2021_vaxzev_0520.indd.pdf
 
36) CDC COVID-19 Response Team ; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 46-51.
 
37) CDC COVID-19 Response Team ; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine-United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 125-9.
 
38) McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016 ; 137 : 868-78.
PubMed
39) 第73回厚生科学審議会予防接種・ワクチン分科会副反応検討部会, 令和3年度第23回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会 (合同開催) 資料. https://www.mhlw.go.jp/content/10601000/000862253.pdf
 
40) Turner PJ, Ansotegui IJ, Campbell DE, et al. Covid-19 vaccine-associated anaphylaxis : a statement of the world allergy organization anaphylaxis committee. World Allergy Organ J. 2021 ; 14 : 100517.
PubMed
41) 厚生労働省. 新型コロナワクチンQ&A. ワクチンを接種すると心筋炎や心膜炎になる人がいるというのは本当ですか. https://www.cov19-vaccine.mhlw.go.jp/qa/0079.html
 
42) Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients : Update from the advisory committee on immunization practices-United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 977-82. doi : 10.15585/mmwr.mm7027e2.
 
43) Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people under age 20 : A population-based analysis. medRxiv, 2021. doi : 10.1101/2021.07.23.21260998.
 
44) Centers for Disease Control and Prevention. linical considerations : myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. https://www.cdc.gov/vaccines/covid-19/clinicalconsiderations/myocarditis.html
 
45) MHRA : Coronavirus vaccine-summary of yellow card reporting-July 22, 2021. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-cardreporting
 
46) European Medicines Agency. AstraZeneca's COVID-19 vaccine : EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-emafinds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
 
47) 日本脳卒中学会, 日本血栓止血学会. アストラゼネカ社 COVID-19ワクチン接種後の血小板減少症を伴う血栓症の診断と治療の手引き・第3版. https://www.jsts.gr.jp/news/pdf/20211117_tts.pdf
 
48) 厚生労働省. 新型コロナウイルス感染症に係る臨時の予防接種実施要領. https://www.mhlw.go.jp/content/000834603.pdf
 
49) European Medical Agency : COVID-19 vaccine safety update Vaxzevria- July 14, 2021. https://www.ema.europa.eu/en/documents/covid-19-vaccinesafety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf
 
50) Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol. 2021 ; 90 : 312-4.
 
51) Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app : A prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022 ; 22 : 43-55.
 
52) Monto AS. The future of SARS-CoV-2 vaccination-Lessons from influenza. N Engl J Med. 2021 ; 385 : 1825-27.
PubMed
P.385 掲載の参考文献
1) Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021 ; 384 : 2092-101.
PubMed
2) Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 ; 384 : 2124-30.
PubMed
3) Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 ; 384 : 2202-11.
PubMed
4) Coronavirus Vaccine-summary of Yellow Card reporting (publishing.service.gov.uk)
 
5) See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021 ; 325 : 2448-56.
PubMed
6) Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015 ; 373 : 252-61.
PubMed
7) Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017 ; 15 : 2099-114.
PubMed
8) Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021 ; 138 : 2256-68.
PubMed
9) Rollin J, Pouplard C, Gruel Y. Risk factors for heparin-induced thrombocytopenia : Focus on Fcγ receptors. Thromb Haemost. 2016 ; 116 : 799-805.
 
10) Perdomo J, Leung HHL, Ahmadi Z, et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun. 2019 ; 10 : 1322.
PubMed
11) Klok FA, Pai M, Huisman MV, et al. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2022 ; 9 : e73-e80.
PubMed
12) Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021 ; 385 : 1680-9.
PubMed
13) ISTH_VITT_Guidance_2.pdf (ymaws.com)
 
14) coronavirus_vipitguidance.pdf (un.org)
 
15) TTS手引き ver.3.3 (jsts.gr.jp)
 
16) Perry RJ, Tamborska A, Singh B, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK : A multicentre cohort study. Lancet. 2021 ; 398 : 1147-56.
 
17) Sanchez van Kammen M, Aguiar de Sousa D, Poli S, et al. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol. 2021 ; 78 : 1314-23.
PubMed
18) Salih F, Schonborn L, Kohler S, et al. Vaccine-induced thrombocytopenia with severe headache. N Engl J Med. 2021 ; 385 : 2103-5.
PubMed
19) Thiele T, Weisser K, Schonborn L, et al. Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia : Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. Lancet Reg Health Eur. 2022 ; 12 : 100270.
PubMed
20) Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia : A review. Expert Rev Hematol. 2019 ; 12 : 685-98.
PubMed
21) Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017 ; 15 : 2099-114.
PubMed
22) Muller J, Buchsel M, Feil K, et al. The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021 ; 138 : 992-6.
PubMed
23) Rizk JG, Gupta A, Sardar P, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis : A review. JAMA Cardiol. 2021 ; 6 : 1451-60.
PubMed
24) Gunther A, Bramer D, Pletz MW, et al. Complicated long term vaccine induced thrombotic immune thrombocytopenia-A case report. Vaccines (Basel). 2021 ; 9 : 1344.
PubMed
25) MAGICapp Guideline : COVID-19 rapid guideline : vaccine-induced immune thrombocytopenia and thrombosis (VITT)
 
26) Lacy J, Pavord S, Brown KE. VITT and second doses of Covid-19 vaccine. N Engl J Med. 2022 ; 386 : 95.
PubMed
P.392 掲載の参考文献
1) Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barre syndrome : a systematic review and meta-analysis. Neuroepidemiol. 2011 ; 36 : 123-33.
PubMed
2) Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barre syndrome. Lancet. 2021 ; 397 : 1214-28.
PubMed
3) Luijten LWG, Leonhard SE, van der Eijk AA, et al. Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain. 2021 ; 144 : 3392-404.
 
4) Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Aca Sci USA. 2004 ; 101 : 11404-9.
 
5) Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979 ; 110 : 105-23.
PubMed
6) Principi N, Esposito S. Vaccine-preventable diseases, vaccines and Guillain-Barre syndrome. Vaccine. 2019 ; 37 : 5544-50.
PubMed
7) Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021 ; 27 : 2144-53.
PubMed
8) Garcia-Grimshaw M, Michel-Chavez A, Vera-Zertuche JM, et al. Guillain-Barre syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol. 2021 ; 230 : 108818.
PubMed
9) Bouattour N, Hdiji O, Sakka S, et al. Guillain-Barre syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine : case report and review of reported cases. Neurol Sci. 2022 ; 43 : 755-61.
PubMed
10) Censcak D, Ungermann L, Stetkarova I, et al. Guillan-Barre syndrome after first vaccination dose against COVID-19 : Case report. Acta Medica (Hradec Kralove). 2021 ; 64 : 183-6.
PubMed
11) Scendoni R, Petrelli C, Scaloni G, et al. Electromyoneurography and laboratory findings in a case of Guillain-Barre syndrome after second dose of Pfizer COVID-19 vaccine. Hum Vaccin Immunother. 2021 ; 17 : 4093-6.
 
12) Waheed S, Bayas A, Hindi F, et al. Neurological complications of COVID-19 : Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021 ; 13 : e13426.
PubMed
13) Trimboli M, Zoleo P, Arabia G, et al. Guillain-Barre syndrome following BNT162b2 COVID-19 vaccine. Neurol Sci. 2021 ; 42 : 4401-2.
PubMed
14) Razok A, Shams A, Almeer A, et al. Post-COVID-19 vaccine Guillain-Barre syndrome ; first reported case from Qatar. Ann Med Surg. 2021 ; 67 : 102540.
PubMed
15) Ogbebor O, Seth H, Min Z, et al. Guillain-Barre syndrome following the first dose of SARS-CoV-2 vaccine : A temporal occurrence, not a causal association. IDCases. 2021 ; 24 : e01143.
 
16) Fukushima T, Tomita M, Ikeda S, et al. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer). QJM. 2022 ; 115 : 25-7.
PubMed
17) Abicic A, Adamec I, Habek M. Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurol Sci. 2022 ; 43 : 1495-7.
PubMed
18) Nishiguchi Y, Matsuyama H, Maeda K, et al. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. BMC Neurol. 2021 ; 21 : 452.
PubMed
19) Dalwadi V, Hancock D, Ballout AA, et al. Axonal-variant Guillian-Barre syndrome temporally associated with mRNA-based moderna SARS-CoV-2 vaccine. Cureus. 2021 ; 13 : e18291.
PubMed
20) Masuccio FG, Comi C, Solaro C. Guillain-Barre syndrome following COVID-19 vaccine mRNA-1273 : A case report. Acta Neurol Belg. 2021 Nov 12 : 1-3. doi : 10.1007/s13760-021-01838-4.
 
21) Matarneh AS, Al-Battah AH, Farooqui K, et al. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clin Case Rep. 2021 ; 9 : e04756.
PubMed
22) Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barre Syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol 2021 ; 90 : 312-4.
 
23) James J, Jose J, Gafoor VA, et al. Guillain-Barre syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination : A case series. Neurol Clin Neurosci. 2021 ; 9 : 402-5.
PubMed
24) McKean N, Chircop C. Guillain-Barre syndrome after COVID-19 vaccination. BMJ Case Rep. 2021 ; 14 : e244125.
PubMed
25) Introna A, Caputo F, Santoro C, et al. Guillain-Barre syndrome after AstraZeneca COVID-19-vaccination : A causal or casual association? Clin Neurol Neurosurg. 2021 ; 208 : 106887.
PubMed
26) Theuriet J, Richard C, Becker J, et al. Guillain-Barre syndrome following first injection of ChAdOx1 nCoV-19 vaccine : First report. Rev Neurol (Paris). 2021 ; 177 : 1305-7.
 
27) Bonifacio GB, Patel D, Cook S, et al. Bilateral facial weakness with paraesthesia variant of Guillain-Barre syndrome following Vaxzevria COVID-19 vaccine. J Neurol Neurosurg Psychiatry. 2022 ; 93 : 341-2.
PubMed
28) Allen CM, Ramsamy S, Tarr AW, et al. Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021 ; 90 : 315-8.
PubMed
29) Shao SC, Wang CH, Chang KC, et al. Guillain-Barre syndrome associated with COVID-19 vaccination. Emerg Infect Dis. 2021 ; 27 : 3175-8.
PubMed
30) Nasuelli NA, De Marchi F, Cecchin M, et al. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. Neurl Sci. 2021 ; 42 : 4747-9.
 
31) Kanabar G, Wilkinson P. Guillain-Barre syndrome presenting with facial diplegia following COVID-19 vaccination in two patients. BMJ Case Rep. 2021 ; 14 : e244527.
PubMed
32) Patel SU, Khurram R, Lakhani A, et al. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 2021 ; 14 : e242956.
PubMed
33) Hasan T, Khan M, Khan F, et al. Case of Guillain-Barre syndrome following COVID-19 vaccine. BMJ Case Rep. 2021 ; 14 : e243629.
 
34) Kripalani Y, Lakkappan V, Parulekar L, et al. A rare case of Guillain-Barre syndrome following COVID-19 vaccination. Eur J Case Rep Intern Med. 2021 ; 8 : 002707.
PubMed
35) Min YG, Ju W, Ha YE, et al. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine : Report of two cases and review of literature. J Neuroimmunol. 2021 ; 359 : 577691.
PubMed
36) Dang YL, Bryson A. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination. BMJ Case Rep. 2021 ; 14 : e246701.
 
37) Finsterer J. Exacerbating Guillain-Barre syndrome eight days after vector-based COVID-19 vaccination. Case Rep Infect Dis. 2021 ; 2021 : 3619131.
PubMed
38) Tiemstra JD, Khatkhate N. Bell's palsy : Diagnosis and management. Am Fam Physician. 2007 ; 76 : 997-1002.
 
39) Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004 ; 350 : 896-903.
 
40) Zhou W, Pool V, DeStefano F, et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines : Reports to the vaccine adverse event reporting system (VAERS) --United States, 1991-2001. Pharmacoepidemiol Drug Saf. 2004 ; 13 : 505-10.
 
41) Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 ; 383 : 2603-15.
PubMed
42) Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 ; 384 : 403-16.
PubMed
43) Shibli R, Barnett O, Abu-Full Z, et al. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy : A population-based study. Lancet Reg Health Eur. 2021 ; 11 : 100236.
 
44) Sato K, Mano T, Niimi Y, et al. Facial nerve palsy following the administration of COVID-19 mRNA vaccines : Analysis of a self-reporting database. Int Infect Dis. 2021 ; 111 : 310-2.
PubMed
45) Burrows A, Bartholomew T, Rudd J, et al. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Rep. 2021 ; 14 : e243829.
PubMed
46) Cellina M, D'Arrigo A, Floridi C, et al. Left Bell's palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine : A case report. Clin Imaging. 2021 ; 82 : 1-4.
 
47) Iftikhar H, Noor SMU, Masood M, et al. Bell's palsy after 24 hours of mRNA-1273 SARS-CoV-2 vaccine. Cureus 2021 ; 13 : e15935.
 
48) Colella G, Orlandi M, Cirillo N. Bell's palsy following COVID-19 vaccination. J Neurol. 2021 ; 268 : 3589-91.
 
49) Martin-Villares C, Vazquez-Feito A, Gonzalez-Gimeno MJ, et al. Bell's palsy following a single dose of mRNA SARS-CoV-2 vaccine : A case report. J Neurol. 2022 ; 269 : 47-8.
 
50) Obermann M, Krasniqi M, Ewers N, et al. Bell's palsy following COVID-19 vaccination with high CSF antibody response. Neurol Sci. 2021 ; 42 : 4397-9.
 
P.401 掲載の参考文献
1) Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022 ; 43 : 3-40.
PubMed
2) Koh JS, Hoe RHM, Chiew HJ, et al. Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines. J Neurol Sci. 2021 ; 430 : 120030.
PubMed
3) 福武敏夫. 神経症状の診かた・考えかた-General Neurologyのすすめ-. 第2版. 東京 : 医学書院 ; 2017. (特に第8章, 第9章)
 
4) Hull M, Parnes M, Jankovic J. Increased incidence of functional (psychogenic) movement disorders in children and adults amid the COVID-19 pandemic. Neurol Clin Pract. 2021 ; 11 : e686-90.
PubMed
5) Machado M, Tarrano C, Mesrati F, et al. Functional movement disorders during the COVID-19 pandemic : back to Charcot's Era at the Salpetriere. Mov Disord. 2022 ; 37 : 432-4.
 
6) Pringsheim T, Ganos C, McGuire JF, et al. Rapid onset functional tic-like behaviors in young females during the COVID-19 pandemic. Mov Disord. 2021 ; 36 : 2707-13.
PubMed
7) Valdes-Florido MJ, Lopez-Diaz A, Palermo-Zeballos FJ, et al. Reactive psychoses in the context of the COVID-19 pandemic : clinical perspectives from a case series. Rev Psiquiatr Salud Ment (Engl Ed). 2020 ; 13 : 90-4.
PubMed
8) Valente KD, Alessi R, Baroni G, et al. The COVID-19 outbreak and PNES : the impact of a ubiquitously felt stressor. Epilepsy Behav. 2021 ; 117 : 107852.
PubMed
9) Brandao PRP, Grippe TC, Pereira DA, et al. New-onset movement disorders associated with COVID-19. Tremor Other Hyperkinet Mov (N Y). 2021 ; 11 : 26.
PubMed
10) Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19 : a systemic review and meta-analysis. Neurology. 2021 ; 97 : e2269-81.
 
11) Clark JR, Liotta EM, Reish NJ, et al. Abnormal movements in hospitalized COVID-19 patients : a case series. J Neurol Sci. 2021 ; 423 : 117377.
 
12) Piscitelli D, Perin C, Tremolizzo L, et al. Functional movement disorders in a patient with COVID-19. Neurol Sci. 2020 ; 41 : 2343-4.
 
13) Garg A, Goyal S, Comellas AP. Post-acute COVID-19 functional movement disorder. SAGE Open Med Case Rep. 2021 ; 9 : 1-5.
PubMed
14) Zariffeh A, Youssef AS, Rizvi F, et al. Post severe acute respiratory syndrome Coronavirus 2 infection tremors in a nonverbal autistic adolescent. Cureus. 2021 ; 13 : e16296.
 
15) Delgado C, Parees I, Jimenez-Huete A, et al. Impact of the COVID-19 pandemic on functional movement disorders : lessons from a specialized clinic. Mov Disord. 2020 ; 35 : 1723-4.
PubMed
16) Nistico V, Goeta D, Gambini O, et al. The psychological impact of COVID-19 among a sample of Italian patients with functional neurological disorders : A preliminary study. Parkinsonism Relat Disord. 2020 ; 78 : 78-81.
PubMed
17) Butler M, Tamborska A, Wood GK, et al. Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines : from cerebral venous sinus thrombosis to functional neurological disorder. JNNP. 2021 ; 92 : 1144-51.
 
18) Linden SC, Carson AJ, Wessely S. Functional neurological disorder after vaccination : a balanced approach informed by history. J R Coll Physicians Edinb. 2021 ; 51 : 330-1.
 
19) Ng JH, Chaudhuri KR, Tan EK. Functional neurological disorders and COVID-19 vaccination. Ann Neurol. 2021 ; 90 : 328.
PubMed
20) Kim DD, Kung GS, Perez DL. Helping the public understand adverse events associated with COVID-19 vaccinations : lessons learned from functional neurological disorder. JAMA Neurol. 2021 ; 78 : 789-90.
 
21) Ercoli T, Lutzoni L, Orofino G, et al. Functional neurological disorder after COVID-19 vaccination. Neurol Sci. 2021 ; 42 : 3989-90.
PubMed
22) Butler M, Coebergh JA, Safavi F, et al. Functional neurological disorder after SARS-CoV-2 vaccines : Two case reports and discussion of potential public health implications. J Neuropsychiat Clin Neurosci. 2021 ; 33 : 345-8.
 
23) Fasano A, Daniele A. Functional disorders after COVID-19 vaccine fuel vaccination hesitancy. J Neurol Neurosurg Psychiatry. 2022 ; 93 : 339-40.
PubMed
24) Garcia-Grimshaw M, Ceballos-Liceaga SE, Hernandez-Vanegas LE. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico : A nationwide descriptive study. Clin Immunol. 2021 ; 229 : 108786.
PubMed
25) Salinas M, Dieppa M.Transient akathisia after the SARS-Cov-2 vaccine. Clin Parkinsonism Relat Disord. 2021 ; 4 : 100098.
PubMed
26) Erro R, Buonomo AB, Barone P, et al. Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson's disease. Mov Disord. 2021 ; 36 : 2219.
 
27) Goss AL, Samudralwar RD, Das RR, et al. ANA investigates : neurological complications of COVID-19 vaccines. Ann Neurol. 2021 ; 89 : 856-7.
PubMed
P.409 掲載の参考文献
1) 日本神経学会. COVID-19ワクチンに関する日本神経学会の見解 (第4版) (2021年8月27日掲載). https://www.neurology-jp.org/covid/index.html
 
2) 多発性硬化症国際連合. 新型コロナウイルス感染症に関する多発性硬化症患者さんへの助言 (2021年6月4日改訂版). http://www.neuroimmunology.jp/jpn/news/MSIF_COVID19_jp.pdf
 
3) Fragoso YD, Gomes S, Goncalves MV, et al. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19. Mult Scler Relat Disord. 2021 : 103321. Epub ahead of print.
 
4) Di Filippo M, Cordioli C, Malucchi S, et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2021 : jnnp-2021-327200. Online ahead of print.
PubMed
5) Sy MY, Fromm E, Doan L, et al. Nicolau syndrome after glatiramer acetate injection in close proximity to administration of SARS-CoV-2 mRNA vaccine. Neurol Neuroimmunol Neuroinflamm. 2021 ; 9 : e1112.
PubMed
6) Ismail II, Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2022 ; 362 : 577765.
 
7) Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021 ; 56 : 103251.
PubMed
8) Dreyer-Alster S, Menascu S, Mandel M, et al. COVID-19 vaccination in patients with multiple sclerosis : Safety and humoral efficacy of the third booster dose. J Neurol Sci. 2022 ; 434 : 120155.
 
9) Schumacher F, Mrdenovic N, Scheicht D, et al. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab : a case-control study (COVID-19VacRTX). Rheumatology (Oxford). 2022 : keac036.
 
10) Shields AM, Venkatachalam S, Shafeek S, et al. SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease : a West Midlands Research Consortium study. Clin Exp Immunol. 2021 ; 207 : 3-10.
 
11) Louapre C, Ibrahim M, Maillart E, et al. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 ; 93 : 24-31.
 
12) Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol. 2022 ; 91 : 89-100.
PubMed
13) Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients : B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021 ; 80 : 1345-50.
PubMed
14) Kornek B, Leutmezer F, Rommer PS, et al. B cell depletion and SARS-CoV-2 vaccine responses in neuroimmunologic patients. Ann Neurol. 2022 : Online ahead of print.
 
15) Konig M, Torgauten HM, Tran TT, et al. Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol. 2022 ; 79 : 307-9.
PubMed
16) Doneddu PE, Spina E, Briani C, et al. Acute and chronic inflammatory neuropathies and COVID-19 vaccines : Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP). J Peripher Nerv Syst. 2021 ; 26 : 148-54.
PubMed
17) Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barre syndrome spectrum associated with COVID-19 : an up-to-date systematic review of 73 cases. J Neurol. 2021 ; 268 : 1133-70.
 
18) Van Looy E, Veenker L, Steyaert A, et al. COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy. J Neurol. 2021 ; 268 : 3129-31.
PubMed
19) Suri V, Pandey S, Singh J, et al. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination. BMJ Case Rep. 2021 ; 14 : e245816.
PubMed
20) Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease : Review of available evidence. J Am Acad Dermatol. 2021 ; 85 : 1274-84.
PubMed
21) Shinjo SK, de Souza FHC, Borges IBP, et al. Systemic autoimmune myopathies : A prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology (Oxford). 2021 : keab773.
PubMed
22) International MG/COVID-19 Working Group. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020 ; 412 : 116803.
 
23) Tagliaferri AR, Narvaneni S, Azzam MH, et al. A case of COVID-19 vaccine causing a myasthenia Gravis crisis. Cureus. 2021 ; 13 : e15581.
PubMed
24) Ruan Z, Tang Y, Li C, et al. COVID-19 Vaccination in patients with myasthenia gravis : A single-center case series. Vaccines (Basel). 2021 ; 9 : 1112.
PubMed
25) Plymate LC, Pepper G, Krist MP, et al. Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab. J Transl Autoimmun. 2021 ; 4 : 100114.
 
P.415 掲載の参考文献
1) World Muscle Society. COVID-19 and people with neuromuscular disorders : World Muscle Society advice -Vaccines. World Muscle Society ; 2021/12/3. https://www.worldmusclesociety.org/news/view/covid-19-and-people-withneuromuscular-disorders-world-muscle-society-advice-vaccines
 
2) Zuckerman JN. The importance of injecting vaccines into muscle. Br Med J. 2000 ; 321 : 1237-8.
 
3) Gyldenlove M, Skov L, Hansen CB, et al. Recurrent injection-site reactions after incorrect subcutaneous administration of a COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021 May 12. doi : 10.1111/jdv.17341
 
4) 日本神経学会. COVID-19ワクチンに関する日本神経学会の見解 第4版. 2021/8/26. https://www.neurology-jp.org/covid/pdf/20210827_01.pdf
 
5) Doneddu PE, Spina E, Briani C, et al. Acute and chronic inflammatory neuropathies and COVID-19 vaccines : Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP). J Peripher Nerv Syst. 2021 ; 26 : 148-54.
PubMed
6) 日本小児科学会予防接種・感染症対策委員会. 小児に対するワクチンの筋肉内接種法について (改訂版). 日本小児科学会 ; 2019/7/28 (2019年8月一部修正). https://www.jpeds.or.jp/uploads/files/201908_kinnnikunaisesshu.pdf
 
7) The American Academy of Neurology Board of Directors. Position statement : COVID-19 vaccination. American Academy of Neurology. 2021/1/27. https://www.aan.com/policy-and-guidelines/policy/position-statements/aanposition-statement-on-covid-19-vaccination/
 
8) Demonbreun AR, Velez MP, Saber R, et al. mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease. Neuromuscul Disord. 2022 ; 32 : 33-5.
PubMed
9) Saito T, Ohfuji S, Matsumura T, et al. Safety of a pandemic influenza vaccine and the immune response in patients with Duchenne muscular dystrophy. Intern Med. 2015 ; 54 : 1199-205.
PubMed

書評

最近チェックした商品履歴

Loading...